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Autophagy is an evolutionarily conserved process that functions to maintain
homeostasis and provides energy during nutrient deprivation and environmental
stresses for the survival of cells by delivering cytoplasmic contents to the lysosomes
for recycling and energy generation. Dysregulation of this process has been linked
to human diseases including immune disorders, neurodegenerative muscular
diseases and cancer.
Autophagy is a double edged sword in that it has both pro-survival and prodeath roles in cancer cells. Its cancer suppressive roles include the clearance of
damaged organelles, which could otherwise lead to inflammation and therefore
promote tumorigenesis. In its pro-survival role, autophagy allows cancer cells to
overcome cytotoxic stresses generated the cancer environment or cancer
treatments such as chemotherapy and evade cell death. A better understanding of
how drugs that perturb autophagy affect cancer cell signaling is of critical
importance to improve the cancer treatment arsenal.
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In order to gain insights in the relationship between autophagy and drug
treatments, we conducted a high-throughput drug screen to identify autophagy
modulators. Our high-throughput screen utilized image based fluorescent
microscopy for single cell analysis to identify chemical perturbants of the autophagic
process. Phenothiazines emerged as the largest family of drugs that alter the
autophagic process by increasing LC3-II punctae levels in different cancer cell lines.
In addition, we observed multiple biological effects in cancer cells treated with
phenothiazines. Those antitumorigenic effects include decreased cell migration,
cell viability, and ATP production along with abortive autophagy. Our studies
highlight the potential role of phenothiazines as agents for combinational therapy
with other chemotherapeutic agents in the treatment of different cancers.
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CHAPTER 1
_________________________________________________________
INTRODUCTION

The American Cancer Society estimates 226,870 new cases of breast
cancers in women and 2,190 new cases in men the United States in 2012.
Although breast cancer cases have declined since 1990, it remains the second
leading cause in cancer related deaths in women in the United States. The ACS
estimates it will claim the lives of 39,510 women and 410 men this year (2). These
statistics provide a strong impetus for studying novel pathways that could help
develop better therapeutics for the treatment of breast cancer.
Chemotherapy is an important tool for the treatment of breast cancers. It can
increase the survival of patients in the adjuvant as well as in the metastatic setting.
However, there are several different mechanisms by which cancer cells have
inherent or acquired resistance to the variety of chemotherapeutic agents used.
Since autophagy is also known as programmed cell death type II, an alternative
form of cell death to apoptosis, it has attracted a lot of interest as a potential target
for cancer therapeutics (3). Indeed, our laboratory has shown that targeting
autophagy can enhance therapeutic effectiveness of some cancer treatments (4).
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AUTOPHAGY
Autophagy is derived from Greek, “auto” meaning self and “phagia” meaning
eating and describes a catabolic process involving a double membraned
phagophore (which forms the autophagosome) and which following fusion with the
lysosome leads to degradation of cytoplasmic contents. It is a highly conserved
mechanism, found in yeasts to mammals (5). There are three major types of
autophagy: microautophagy, chaperone-mediated autophagy (6), and
macroautophagy (7). These are defined by the method by which they deliver their
cytoplasmic cargo to the lysosomes. The focus of this study is macroautophagy,
hereafter referred to as autophagy. Autophagy is an important evolutionarily
conserved process of cellular maintenance, differentiation, development of
mammals, and cell survival. Autophagy is also known as a cell death mechanism;
programmed cell death type II (PCD II), a cell death distinct from apoptosis which is
known as programmed cell death type I (PCD I) (8). Disruption or dysregulation of
autophagy is implicated in many diseases including microbial infection, heart
disease, neurodegenerative diseases, and cancer (9).

Physiological functions of autophagy
Autophagy is constitutively activated and occurs at a basal level in cells and
functions as a homeostasis mechanism. It serves as a quality control in cells,
limiting the accumulation of aggregated proteins, damaged organelles and
macromolecules by sequestering them for degradation through the lysosomal
system. By catabolic degradation of cellular components, autophagy also serves as
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a cellular recycling system for the generation of energy and macromolecules for
biosynthesis in cells (10). This function is especially important in ensuring cell
survival by maintaining cellular energy level during limited glucose, oxygen, and
amino acid conditions (11). Additionally, by clearing cells of damaged organelles
and aggregated proteins, autophagy prevents them from building up and reaching
toxic levels which could result in tissue damage, inflammation, and cancer
development (12), (13),(14), (15), (16), (17).

Autophagy functions as quality control of proteins and organelles
Autophagy functions as quality control of organelles, aggregated proteins
and ubiquitinated protein. Other systems of protein quality controls in the cells are
mediated through the endoplasmic reticulum (ER) and the proteasomal degradation
pathway.
The ER is a cytosolic compartment which functions in folding and
modification of newly synthesized secretory, cell surface or organelle proteins and
also functions as one of the cell’s calcium reservoirs (18). Soluble proteins which
are misfolded are transported out of the ER to be targeted for ubiquitination and
proteasomal degradation in the cytosol by ER-associated degradation (ERAD) I
pathway (19). Insoluble, misfolded or aggregated proteins are processed through
activation of autophagy, also known as the ERAD II pathway (20). During adverse
conditions such as impaired glycosylation, oxidative stress, hypoxia, nutrient
deprivation, bacteria or viral infection, ER function is perturbed and has exceeded
its capacity to fold proteins, ER stress ensues (21), (22). Accumulation of unfolded
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proteins in the ER lumen can cause ER stress which activates the Unfolded Protein
Response (UPR), a group of pathways which function to restore ER homeostasis
(23). There are three known transducers of ER stress which sense ER lumen
unfolded protein levels to activate the UPR. These include the RNA-dependent
protein kinase like ER kinase (PERK), activating transcription factor 6 (ATF6) and
inositol-requiring enzyme 1 (IRE1). The UPR is an adaptive signaling pathway that
shifts protein synthesis from global proteins to the synthesis of chaperones and
other proteins involved in the restoration of the function of the ER. The outcome of
the activation of UPR is context dependent which could result in reduction of
proteins entering the ER, increased protein clearance from the ER, or increased
protein folding capacity of the ER. During sustained or irreversible ER stress, the
UPR changes from a cytoprotective function and initiates apoptotic cell death (24),
(25). ER stress is also an activator of autophagy (26), (27, 28), (28), whereby the
ER is a major cargo of the autophagosome. Here, autophagy functions as a prosurvival process to remove ER that contains unfolded proteins (27). ER stress, like
autophagy functions as a pro-survival or pro-death mechanism which is cell and
context dependent (29). ER stress can induce autophagy (24); on the other hand,
we have previously shown that abortive autophagy is an inducer of ER stress (30).
Although ER stress and autophagy are distinct homeostatic cellular pathways, they
are interlinked and share common regulatory proteins. The connection between
autophagy and ER is through Beclin 1 through its regulation at the ER membrane
(31). Interestingly, several stimuli which activate autophagy also activate ER stress.
Such stimuli include nutrient deprivation, energy perturbation, DNA damage, and
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oxidative stress. The UPR is upregulated in many tumor cells, whereas it is
quiescent in normal cells (32).
The ER, ubiquitin-proteasomal degradation pathway, and autophagy are
three mechanisms that function in cellular protein quality control. These three
protein quality control mechanisms are compensatory to each other; when cells are
unable to recover stresses through the activation of either one of them alone,
activation of the other pathways occur (12), (33).

Autophagy is a multi-step process
Autophagy begins with a nucleation step for the formation of a phagophore,
or isolation membrane in the cytosol. The phagophore undergoes elongation and
forms a cup-like structure that encloses cytosolic components which include
organelles and aggregated proteins for the delivery to the lysosome. The doublemembrane vacuole forms the autophagosome. During maturation, the
autophagosome expands and fuses with a late endosome (11). It subsequently
fuses with a lysosome to form an autophagolysosome (or autolysosome). At the
final stage of the autophagosome process, the enzymes of the lysosome degrade
the autolysosome’s contents and provide metabolic substrates as energy source or
as building blocks in the cell (34) (FIGURE 1). This process occurs at a basal level
in all cells, but can rapidly be upregulated by adverse conditions such as nutrient
deprivation, growth factor withdrawal, cytotoxic stress, hypoxia, protein aggregates
and metabolic stress (35),(10),(36).
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The core regulators of the autophagosome machinery
The regulation of the autophagosomal process is coordinated by autophagy
related proteins (Atg) originally discovered and studied in yeast systems (37) (38)
(39), (39, 40), (38). Over 30 mammalian homologues of the yeast autophagy
related genes have been identified (41). Core Atg genes regulate the autophagic
process through the formation four complexes. The first complex is the Atg1/Unc51 like kinase (ULK) complex which is controlled by mTOR phosphorylation. The
second complex consists of Vps34, a class-III phosphatidylinositol 3-kinase (PI3K),
and Vps15 form a complex with Beclin 1, the homolog of yeast Atg6 (42), Bif-1
(Bax-interacting factor -1), and UVRAG (ultraviolet irradiation resistance associated
gene) (43) which is involved in the nucleation of the phagophore. The elongation of
the membranes is mediated through two complexes, which coordinate
ubiquitination-like modifications of target proteins: the Atg12-conjugation and the
LC3-modification system (44), (45), (41)(FIGURE 2). The Atg12 complex is
necessary for the formation of the pre-autophagosomal structures and the
modification of LC3 is required for the elongation and formation of autophagosomes
(46). The first ubiquitination-like steps involve conjugation to covalently link Atg12
to Atg5. This occurs through the activation of Atg12 by Atg7 followed by Atg10
mediated transfer to Atg5 (47). Atg12-Atg5 then complexes with Atg16,
subsequently associating with the phagophore (48).
LC3, the mammalian ortholog of the yeast Atg8 protein, was originally
isolated as a microtubule-associated protein and named microtubule-associated
protein 1 light chain 3 (LC3) (49). It exists as a soluble pro-LC3 form which
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undergoes several ubiquitination-like modifications upon autophagy induction to
eventually associate with the precursors of the autophagosomal structures and the
autophagosomes (50). Pro-LC3 undergoes cleavage leading to exposure of a
carboxyl terminal glycine to form LC3-I (46). LC3-I is activated by Atg7 (E1-like
protein) and is subsequently transferred to Atg3 (E2-like protein) for modification to
LC3-II (51). Prior to autophagy induction, LC3 is soluble and is distributed
throughout the cytosol. Upon autophagy induction, LC3 is modified to LC3-I and
becomes lipidated with phosphoethanolamine (PE), forming LC3-II. LC3-II then
associates with the inner and outer membrane of the autophagosomes. Once the
autophagosomes fuses with the lysosomes, the outer membrane associated LC3- II
is removed from PE by Atg4 for recycling (52), (53),(51) and the LC3-II on the inner
the membrane is degraded by lysosomal enzymes. Upon autophagy completion,
the Atg proteins are recycled (54).

Monitoring autophagy
Autophagosomes can be monitored in live or fixed cells using fluorescent
microscopy with the use of a green fluorescent protein linked to LC3 (GFP-LC3) to
track its localization changes (55). Since autophagy is a dynamic process, blocking
autophagic signaling network or flux can result in a build-up of the LC3-II marker.
The LC3 reporter for autophagy therefore must be used in conjunction with other
assays such Western blot analysis and ultrastructural studies by electron
microscopy (EM) to confirm the increase in autophagosomes (56). The activity of
autophagy is measured by determining autophagic flux by measuring the
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degradation of one of its substrate, p62. p62 protein, also known as SQSTM1, is a
protein involved in diverse cellular signaling pathways, having roles in transcription
factor activation, inflammation, cell survival and cellular stress functions (57). In
addition to associating with ubiquitin, p62 also interacts with LC3 and localizes to
autophagosomes where it is a substrate of autolysosomal degradation (58), (59).
Increased p62 levels in the cells, is consistent with autophagic flux being blocked
(60), (12).
The completion of the autophagy process involves the delivery of
autophagosomal contents to lysosomes for degradation. Monitoring the
autophagosomal to lysosomal fusion step of the autophagy pathway can be
accomplished by use of a green fluorescent protein, linked to a red fluorescent
protein (GFP-RFP) and fused to LC3. With this reporter, LC3 bound on
autophagosomes fluoresces red and green, but upon fusion with the lysosome, it
loses the green fluorescence of GFP because GFP is more sensitive to lysosomal
pH (61). In certain experimental conditions, the lysosomal function is impaired and
both GFP and RFP signals persist. Thus, when GFP and RFP persist, this indicates
the autophagosome did not fuse with the lysosome. Vesicles which only show RFP
are fused autolysosomes (61).
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Amphisome or

Adapted from Trends in Cell Biology. 21:387-92 (2011)

FIGURE 1: Multi-steps of autophagy. Autophagy is a multi-step process
beginning with (1) vesicle nucleation to form a phagophore, which (2) elongates to
form a C- cup which encloses to form a double-membrane vesicle (the
autophagosome) engulfing cytoplasmic materials (organelles, and polyubiquitinated
and aggregated proteins). The autophagosome (3) matures and can either fuse
with late endosomes to form an amphisome or (4) fuse directly with the lysosome to
form the autophagolysosome or autolysosome.
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FIGURE 2: Ubiquitin-like regulation of autophagosomal pathway.
Key regulatory proteins of the autophagy pathways undergo conjugation and
modification by two ubiquitin-like modifications. Atg12- conjugation is required for
formation of the pre-autophagosomal structures and LC3- modification is necessary
for the formation of autophagosomes. Adapted from Trends in Cell Biology. 21:38792 (2011).
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AUTOPHAGY AND CANCER
The importance of autophagy in cancer has clearly been recognized by the
scientific research community as seen in the numerous clinical trials involving
manipulation of autophagy for cancer treatment (http://www.clinicaltrials.gov) (62).
Although autophagy is an attractive target for cancer therapy development, there is
much ongoing discussion as to whether it should be stimulated or inhibited for
anticancer strategy. Due to its contradictory roles in cell survival, it is often referred
to as a double- edged sword. Autophagy’s dual roles as a cell death and cell
survival mechanism must be understood based on cellular context. Currently, the
evidence largely supports the role of autophagy as tumor suppression in the earlier
stage of transformation but changes to supporting tumor survival in advanced
cancers (62). Autophagy’s pro-tumorigenic or tumor suppressive role is dynamic
and is determined by several factors which include the tumor stage, cellular status,
and tissue of origin (63).
The link between autophagy and cancer was through the discovery of the
tumor suppressor Beclin 1(64). Beclin 1 expression level is lower in certain cancer
lineages as compared to normal cells. When Beclin 1 was re-introduced into the
cancer cell lines with low Beclin 1 levels, in vivo tumorigenesis of xenografts was
suppressed. Beclin 1 is monoallelically deleted in many human cancers including
breast, ovarian, prostate, and brain tumors (65), (66). Beclin 1’s role as a tumor
suppressor is further supported by findings that the domain required for Vps34
binding for autophagy induction, is the domain which confers its tumor suppressive
function (67), (64). It has also been observed that deficiency in other autophagy
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genes such as Atg genes increased cells’ susceptibility to tumorigenesis (68), (69).
The Mizushima laboratory generated mouse models with deletion in Atg5 in various
tissues. They showed that conditional deletion of Atg5 in liver led to development of
benign liver tumors (68); Inami et al. found similar results with conditional deletion of
Atg7 (70). Both groups showed that although benign tumors developed, they were
not able to progress to invasive tumors.
Accumulating evidence suggests that autophagy plays a protective role in
advanced tumors, permitting the cells to survive the cytotoxic and metabolic stress
of chemotherapeutics (71), (62), (72). Activation of autophagy in response to
cancer therapies including radiation and chemotherapy has been attributed to the
development to drug resistance. Therapy induces cellular stresses such as
elevated ROS production, accumulation of ER chaperones and p62, activation of
DNA damage responses, genomic damage, chromosomal instability, and cytokine
production which could lead to inflammation and cell death. Autophagy mitigates
these stresses by sequestering the damaged organelles and toxic byproducts for
degradation to re-establish homeostasis.
There is a large body of pre-clinical data showing that blocking autophagy
enhances therapeutic efficacy of different chemoagents. Following inhibition of
autophagy activation as a pro-survival mechanism in response to the insult of the
treatments, the cells succumb to the stress mediated by the therapy (73).
Autophagy in its cytoprotective role has been attributed to cancer cell resistance to
therapy in MCF-7 cells (74). Cancer cells treated with cytotoxic agents which
results in DNA damage upregulate autophagy to delay cell death by sequestering
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damaged mitochondria to the autophagosomes for degradation and delaying
apoptosis (74). Activation of autophagy in response to perifosine treatment resulted
in decreased cytoxicity in chronic myeloid leukemia cells (CML); when autophagy
was inhibited, cell killing by perifosine was enhanced (75). Inhibition of autophagy
by desmethylclomipramine enhanced the cytotoxic potential of doxorubicin in breast
cancer cells (76). Together, these evidence support autophagy inhibition as a
therapeutic strategy.

Targeting differences in autophagy in cancer versus normal cells
Since autophagy impacts many cellular functions there are significant
challenges in developing targeted therapy with low toxicity to normal cells.
Targeting differences between cancer and normal cells such as autophagy
activation levels or metabolic differences could offer therapeutic opportunities with
decreased toxicity to normal cells.
Several studies demonstrate that cancers driven by the K- Ras oncogene
have elevated autophagy. It is proposed that Ras activation reprograms metabolic
pathways, making the cells dependent on autophagy to survive these metabolic
stresses. These cancers are addicted to autophagy for survival and are especially
sensitive to autophagy inhibition (63). Mancias et al. compared of autophagy levels
in high and low grade pancreatic cancer cells with K-Ras mutations against normal
pancreatic ductal epithelium and showed that K-Ras mutated cells had elevated
basal autophagy. Genetic and pharmacological inhibition of autophagy in the K-Ras
mutated cells blocked their tumorigenic potential in vitro as well as in vivo. The K-
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Ras mutated cells’ metabolism was dependent on autophagy and inhibition of
autophagy caused decreased oxidative phosphorylation. Eileen White’s laboratory
also reported that cancers driven by the K-Ras oncogene were dependent on
autophagy for survival and tumor transformation. They reported that when high
levels of H-Ras or K-Ras; often found in human tumor cells, were introduced into
non-tumorigenic mouse kidney epithelial cells, these cells had elevated autophagy
levels. This was observed in several human cancer cell lines which included
bladder, lung and pancreatic cancer cell lines (77). The authors proposed that
activated Ras mutations placed high metabolic demands on the cells, thus forcing
them to rely on autophagy to provide catabolic substrates to meet the energy
demands for survival, growth and proliferation. When the K-Ras oncogene was
expressed in the MCF10-A non-tumorigenic human breast cells, they required high
basal autophagy in order to undergo tumor transformation which was abrogated
when autophagy was inhibited genetically or pharmacologically (78). These
findings showed a synthetic lethal interaction between Ras activation and
autophagy deficiency (77), (79). Additionally, Ras driven cancers are also
dependent on autophagy for glucose uptake and glycolytic flux as MEFs cells
deficient in autophagy showed decreases in both glucose flux and uptake (80).
Because the Ras mutated cells already have high levels of autophagy, they are not
able to upregulate autophagy any further when faced with additional stressors in
order to adapt and survive. The mechanism by which Ras driven cancers become
addicted to autophagy is largely due to impairment of acetyl-CoA production which
is important to maintain the tricarboxylic acid (TCA) cycle. Ras impairs acetyl-CoA
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production through three mechanisms: activation of lactate dehydrogenase (LDH)
causing pyruvate depletion; activation of pyruvate dehydrogenase kinase 1(PDK1)
leading to pyruvate dehydrogenase (PDH) inhibition; and by inhibiting the AMPactivated protein kinase (AMPK) which results in blocked mobilization of lipid stores
and β-oxidation. In doing so, the cells must rely on autophagy for fatty acids, and
amino acids for acetyl-CoA synthesis as the supply normally obtained through
pyruvate and β-oxidation is no longer available (72). One of the consequences of
Ras’ effects on acetyl-CoA production is decreased mitochondrial life span. Ras
causes depletion of mitochondrial TCA cycle substrates and impairs biogenesis of
new mitochondria due activation of HIF1 (81). Without functional autophagy to
provide the TCA cycle substrates for mitochondrial respiration, the mitochondria
become ineffective in providing the energy required to support tumorigenesis (82).
In developing cancer therapies, the goal is to target cancer cells while limiting
toxicities to normal cells. As such, we are essentially searching for the cancer’s
Achilles’ heel (83). Since solid tumors undergo rapid cell proliferation, they have
high metabolic demands and often have outgrown the vascular supplies that sustain
them, and undergo nutrient deprivation, hypoxia and are more dependent on
autophagy than normal cells. Thus autophagy is a potential target for the
development of therapeutic strategies. For certain cancers driven by the Ras
oncogene, autophagy addiction also offers opportunities for targeting differences
between the tumors and the normal surrounding cells.
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PHENOTHIAZINES
Phenothiazines are in important family of drugs which are mostly known for
their antipsychotic properties. Chlorpromazine was the first antipsychotic developed
and holds an important place in the history of psychiatry. Phenothiazines were the
mainstay of treatment for psychotic ailments for the 1950s to the 1990s, but have
been replaced by second generation antipsychotics with decreased side effects.
However, they remain in use today; phenothiazines such as chlorpromazine and
fluphenazine continue to be on the World Health Organization’s List of Essential
Medicines (84).
Phenothiazines are tricyclic compounds containing a sulfur and a nitrogen
with the structural formula S(C6H4)2 NH (FIGURE 3). Subgroups of phenothiazines
are divided based on the substitution on the nitrogen residue: the aliphatic,
piperidine, and piperazine groups. Different substitutions on the core ring confer
specificity to different cellular targets. The aliphatic side chains confer the least
hydrophobicity, and therefore are not as effective in crossing cellular membranes.
Phenothiazines mediate their antipsychotic effects by inhibiting the
interaction of dopamine and its dopamine receptor type 2 (D2) (85), (86), (87).
Phenothiazines also function as antagonists against other neurological transmitter
receptors such as the serotonin (5HT2A), muscarinic (M1), adrenergic (α1) and
histamine (H1) receptors, but their interactions are not as strong as dopamine
receptor interaction (88), (89). Common side effects of the original phenothiazines
include drowsiness and sedation. New generations of phenothiazines have curbed
these side effects, but development of tolerance over time remains a problem.
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Phenothiazines are also alpha-adrenergic blockers and not indicated for treatment
of patients with cardiovascular diseases due to increased pulse rate and
hypotension. All antipsychotic drugs including phenothiazines have potential of
causing tardative dyskinesia syndrome after long-term and at high dose usage.
This is manifested as involuntary rhythmic facial muscular movements.
Phenothiazines and their derivatives have an approximate half-life of 30 hr in
patients. They are metabolized by the liver into at least 12 different metabolites
which are generally excreted in the urine. In the blood, phenothiazines are heavily
bound to plasma proteins, especially albumin.
The parental phenothiazine core ring structure itself has many diverse
pharmacologic activities including antioxidant, antihelminthic, and antiseptic
activities (90). Chlorpromazine is the proto-type antipsychotic, but many other
phenothiazines are also important and used in the clinical setting for different
treatments. Examples of other phenothiazines are promethazine which has
antihistamine activity and thioridazine which is indicated for antipsychotic treatments
(84). Phenothiazines have a long established history in the clinics and are well
tolerated, therefore continue to be used for development of new therapeutic
applications. The most interesting activities of phenothiazines as pertaining to our
study are phenothiazines antitumor activities (91), (92), (93).
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Expression of dopamine receptors outside of central nervous system
Dopamine receptors are predominantly expressed in the central nervous
system (94), but they have also been reported to be found in other tissues (95).
Dopamine receptor expression has been reported in the pituitary gland, in the
peripheral nervous system along with some tissues such as the kidney, adrenal
gland, and cardiovascular system (94), (95). Studies have shown that various types
of tumors which included pancreatic, non-small cell lung cancer, prostate, colon
expressed dopamine receptors (96), (97).
Sokoloff et al. conducted a study of 7 human tumor cell lines; pertinent to our
studies, were the SKBR-3 and MCF-7 breast cancer lines. They reported that the
breast cancer cell lines MCF-7 had no dopamine D2 receptors, and SKBR-3 cells
had 38± 6 dopamine D2 receptors per cell (98).
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FIGURE 3: Structure of phenothiazine S(C6H4)2NH. The parental phenothiazine
ring is a sulfur and nitrogen tricyclic ring. It has been used extensively for the
development of drugs through backbone modifications and substitutions.
Substitutions at different positions on the parental ring changes the specificity of
phenothiazines to different cellular targets.
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Phenothiazines and cancer
Phenothiazines already play an important role in the cancer setting where
they are prescribed for management of nausea and emesis which are often
associated with advanced stages of cancers and chemotherapy (99). Their
inclusion in cancer treatment helps improve the quality of life of patients undergoing
chemotherapy and ensures completion of the treatment by alleviating discomforts of
nausea and vomiting (100). Additionally, as antiemetics, phenothiazines prevent
the reflexive regurgitation of oral medications and ensure patients receive full dose
benefits. As sedative antipsychotics, they are prescribed to alleviate anxiety
experienced by cancer patients (101). While the antiemetic and sedative role of
phenothiazines are important to cancer patients, many studies have shown that
phenothiazines also possess anti-proliferative potential against cancer cells.
Pre-clinical and clinical studies have shown that several drugs of the
phenothiazine family have anti-proliferative and anti-neoplastic properties in diverse
human cancer cell lines; these include non-small cell lung, breast, melanoma,
lymphoblastoma and many other types of cancers (102), (103), (104).
Chlorpromazine was shown to enhance the efficacy of the antineoplastic agent
mitomycin C in mice models; inhibition of tumor formation was also accompanied by
prolonged survival (105). CPZ was also shown to synergize with pentamidine to
inhibit antiproliferation of cancer cells in vivo (106). In vitro studies show that
phenothiazines can reverse multidrug resistance in human breast carcinomas (107).
For instance, CPZ potentiates efficacy of tamoxifen and doxorubicin in breast
cancer cells, the proposed mechanism by which CPZ enhances the toxicity of these
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drugs was through its inhibition of drug efflux from the cells (108). Phenothiazines
have been shown to inhibit the membrane efflux pump P-glycoprotein, which
mediates drug multidrug resistance (MDR) (109). Phenothiazines have also been
reported to downregulate the epidermal growth factor receptors (110), making them
potential agents for the treatment of cancers with upregulated EGFR activation
(111), (112), (113). The anti-proliferative properties of phenothiazines in different
types of cancers have also been proposed to be due to their action as calmodulin
regulators (114), (115), (116). Other reported anti-tumor activities of CPZ included
enhancing sensitivity of cancer cells to radiation (117), and inhibition of energy
metabolism of hypoxic cells (118). Together, these properties make CPZ and its
derivatives attractive agents for development as anti-tumor therapy towards solid
tumors which have hypoxic centers and which are resistant to therapy. Additionally,
recently phenothiazines have been proposed to modulate autophagy, however
mechanistic underpinnings have not been explored and these studies have not
been followed-up (119) ,(120).
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Dissertation Overview
The overall aim of this dissertation is to understand how modulation of
autophagy in cancer cells affects cell viability and to determine whether
autophagy could be targeted for cancer therapy.

Currently, there is limited availability of pharmacological modulators of autophagy
with limited toxicities to normal cells. We therefore sought to identify novel
modulators of autophagy. To accomplish this aim, we developed and implemented
a cellular image-based high-throughput screen (HTS) to identify perturbants of
autophagy in cancer cells. We used a compound library of off-patent FDA approved
drugs and biologically active compounds to increase the likelihood that our findings
would be clinically relevant and eventually be brought to the clinic. The highest
ranking perturbants in our screen were identified as positive “hits” and were
validated in secondary assays. The largest group of compounds identified in our
screen as modulators of autophagy belonged to the phenothiazine family, and
therefore became the focus of our studies. We sought to understand how
modulation of autophagy by phenothiazines affects tumorigenic potential such as
cell viability, invasion and clonogenic potential. Because autophagy is closely
linked to cell energy metabolism, we wanted to understand whether phenothiazines
affect cellular ATP levels. We also sought to determine if antitumorigenic effects
mediated by the phenothiazines were inherent to the parental phenothiazine ring
structure. We therefore conducted comparative structural functional studies of
various representative phenothiazines. In general, all of the actions of the
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phenothiazines in cancer cells paralleled their known structural functional activities
as antipsychotics. This raised the possibility that the anti-tumorigenic potentials of
different phenothiazines are mediated through their properties as dopamine
receptor antagonists. We researched the literature for the status of dopamine
receptor expression in the cancer cells that were in our study and determined that
the breast cancer cell lines we used either had no dopamine receptors or low
expression of dopamine receptors; yet autophagy modulation and cell death was
observed. Therefore the antitumorigenic effects of phenothiazines were unlikely to
be mediated through binding with dopamine receptors. Since breast cancer is the
most common malignancy in women and the second leading cancer related death
in women worldwide, we decided to focus on breast cancer as our model to study
phenothiazines’ modulation of autophagy in cancer cells in vitro as well as in vivo.
Additionally, we conducted a human xenografted mice study to determine if
the findings our in vitro studies were replicated in vivo. We conducted a protein
array analysis of the expression levels of proteins involved in cancer cell signaling
pathways to determine if there were differences in signaling in tumors that showed
response to our drug treatment as compared to tumors that did not show response.
We analyzed protein expression profiles of tumors of different lineages treated with
perphenazine to determine if our findings are generalized to different tumors, and if
certain mutational backgrounds, or tissue of origin rendered them more sensitive to
our drug. Findings in this study indicate that phenothiazines (combined with other
agents) are viable candidates for development for antitumor strategy and warrant
further investigation.
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MATERIALS AND METHODS

CHAPTER 2

_________________________________________________________
Compounds and reagents
Rapamycin was purchased from Cell Signaling Technology (Danvers, MA).
Gleevec (Imatinib) was a kind gift from Dr. Seiji Kondo at MD Anderson Cancer
Center. The Prestwick compound library (Prestwick Chemicals, Washington, DC)
was a generous gift from the John S. Dunn Foundation through the Gulf Coast
Consortia for Chemical Genomics. Phenothiazine compounds: Chlorpromazine,
Chlorpyramine, Perphenazine, Promethazine, Promazine, Temozolomide, 2deoxyglucose and Bafilomycin A1 were all from Sigma-Aldrich (St. Louis, MO). ZVAD was from R&D systems (Minneapolis, MN). All compounds were dissolved in
DMSO unless indicated otherwise. Control experiments showed that DMSO had no
effect on any of the parameters measured. Earle’s Balanced Salt Solution (EBSS)
was from Hyclone, Thermo Scientific.
Cell lines
Human breast cancer cell lines were obtained from the American Type Culture
Collection (ATCC) (Manassas, VA). MDA-MB-231, MDA-MB-468, MCF-7, BT-549,
SKBR-3, ovarian cell lines SKOV-3, OVCAR-3, prostate cell lines LNCaP, PC-3 and
melanoma cell lines SKMEL-5, MEWO, and WM-35 were maintained in RPMI 1640
medium supplemented with heat-inactivated 5% fetal bovine serum (FBS). Mouse
embryonic fibroblasts (MEFs) and U2-OS cells were cultured in DMEM medium
supplemented with heat-inactivated 5% FBS. MCF-10A non-malignant human
mammary epithelial was maintained in DMEM/F12 with 5% horse serum, 10 μg/ml
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insulin, 0.5mg/ml hydrocortisone, 20 ng/ml EGF and 100 ng/ml cholera toxin. All
cells were maintained at 37 C at 5% CO2 at sub-confluent density to prevent
induction of autophagy. All cell lines were validated by STR DNA fingerprinting
using the AmpFℓSTR Identifier kit according to manufacturer’ instructions (Applied
Biosystems, Carlsbad, CA). The STR profiles were compared to known ATCC
fingerprints (www.ATCC.org), Cell Line Integrated Molecular Authentication
database (CLIMA) version 0.1.200808, and to the MD Anderson fingerprint
database.
TISSUE

CELL LINE

MUTATIONAL STATUS

CLINICAL
SUB-TYPE

ER
Status

Breast

BT-549

RB1, TP53, PTEN

Basal-like

ER-

Breast

MCF-10A

None detected

Triple negative
Basal

ER-

Breast

MCF-7

CDKN2A, PIK3CA

HR+, luminal

ER+

Breast

MDA-MB-231

BRAF, CDKN2A, KRAS,
TP53

Triple negative

ER-

Breast

MDA-MB-468

PTEN, RB1, TP53, SMAD4

Triple negative

ER-

Breast

SKBR-3

None detected

HR+,

ER-

Breast

T47D

PIK3CA, TP53

HR+, Luminal

ER+

Breast

ZR75-1

KRAS, PTEN

HR+, Luminal

ER+

Melanoma

MEWO

CDKN2A, TP53, NF1

Melanoma

SKMEL-5

BRAF, CDKN2A, STK11

Melanoma

WM 35

BRAF

Ovarian

OVCAR-3

TP53

Ovarian

SKOV-3

CDKN2A, PIK3CA, TP53

Prostate

PC-3

PTEN, TP53

Prostate

LNCaP

PTEN

Bone

U2-OS

None detected

Table 1. Mutational status and clinical classification of cell lines used in our studies.
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Fluorescent image based high-throughput drug screen for autophagy
modulators
The GFP-LC3 construct was a kind gift from Dr. Noboru Mizushima; Tokyo Medical
and Dental University, Japan). U2-OS osteosarcoma cells stably expressing the
GFP-LC3 construct were seeded at a density of 5,000 cells/ 100 µl media in blackwalled clear bottom 96-well tissue culture plates. Cells were allowed to attach
overnight. The following day, compounds were added to each well and incubated
for 48 hr at 37° C with 5% CO2. Cells were post-fixed with 4% paraformaldehyde in
PBS for 15 min in the dark at room temperature. Cell nuclei were stained with
Hoechst 33342 (1:1,000 dilution) for 5 min, washed with PBS, and maintained in
200 µl PBS for fluorescent microscopy imaging at 20X magnification on an IN Cell
Analyzer 1000 Cellular Imaging and Analysis system which is equipped with a
Nikon fluorescent microscope with an automated stage (GE Healthcare,
Piscataway, NJ). 5 fields were captured per well for each 96-well plate. The nuclear
regions were segmented using the Hoechst 3334 dye, and cytoplasmic regions
were identified using the GFP signal. Only GFP positive cells were quantified for
autophagy analysis. Autophagosome formation was determined for each cell using
the multi-target analysis algorithm provided with the IN Cell Analyzer. Results were
shown as percent autophagy.
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siRNA transfection
Non-targeted RISC-Free control (D-001220-01-05), Beclin-1, Atg5 (L-004374-00),
and Atg12 (L-010212-00) siRNAs (Dharmacon, Lafayette, CO) were diluted in
molecular grade RNase-free water. Cells were plated in 6 cm tissue culture dish 24
hr prior to transfection at 40%-50% confluency. The media was replaced with fresh
media prior to siRNA transfection by reverse transfection at 10 nM final
concentration in 2 ml OPTIMEM I using RNAi Max transfection reagent (Invitrogen,
Carlsbad, CA) and prepared according to the manufacturer’s instructions. 24 hr
after transfection, fresh media was added and the cells were transfected again with
siRNA. 48 hr from the 1st transfection, the cells were treated with perphenazine at
the indicated concentration. The cells were collected at the 72 hr after the 1st
siRNA transfection (24 hr post drug treatment) for analysis by Western blot analysis.

SDS-PAGE and western blot analysis
At the endpoint of each experiment, cell culture dishes were placed on ice; both
floating cells and adherent cells were collected and lysed in ice-cold lysis buffer (1%
Triton X-100, 50 mM Hepes, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
100 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 10% glycerol, 1 mM
phenylmethylsulfonyl fluoride (PMSF), and 10 g/ml aprotinin). Whole cell lysates
were centrifugated at 13,000 rpm for 10 min at 4°C. The supernatants were
collected for subsequent analysis. Cellular protein concentration in the supernatant
was determined by BCA reaction (Pierce, Rockford, IL). The proteins were prepared
in denaturing sample buffer adding 1 part 4x SDS sample buffer (40% Glycerol, 8%
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SDS, 0.25M Tris-HCl, pH 6.8, 10% (2-mercaptoethanol) to 3 parts lysate. The
sampled were heated to 95° F for 15 minutes. The proteins were separated by
SDS-PAGE and transferred to PVDF membranes. The membranes were blocked
with 5% (w/v) BSA in TBS-T (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween
20) for 1 hr at room temperature. Membranes were incubated overnight at 4°C with
antibodies in 5% (w/v) BSA in TBS-T. The membranes were briefly washed in TBST and incubated with the appropriate HRP-conjugated secondary antibody for one
hr at room temperature. The membranes were washed extensively with TBS-T and
the proteins were visualized by enhanced chemiluminescence (ECL) (Amersham
Biosciences, Piscataway, NJ). Films were scanned using a Canoscan 600 LiDe
scanner (Cannon USA Inc., Lake Success, NY).

Antibodies
The following antibodies were used: anti-p62 (BD Biosciences, Franklin Lakes, NJ),
anti-LC3 (Novus Biologicals, Littleton, CO), anti-cleaved caspase 3, anti-cleaved
PARP, anti-Atg5, anti-Atg12, anti-beclin-1 (Cell Signaling Technology, Beverly, MA),
anti-β-actin (Sigma-Aldrich, St. Louis, MO), and mouse monoclonal antibody to
GAPDH (Ambion, Austin, TX) and were used at the dilutions recommended by the
manufacturers. HRP-conjugated goat anti-rabbit secondary antibody and HRPconjugated goat anti-mouse secondary antibody (Bio-Rad, Hercules, CA) were used
at a 1:2,500 dilutions in 5% (w/v) milk in TBS-T.
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Transmission electron microscopy (TEM)
Cells were seeded in 6-well tissue culture plates and treated with DMSO,
chlorpromazine, perphenazine, phenothiazine at the indicated doses. After
treatment, cells were fixed with a solution containing 3% glutaraldehyde plus 2%
paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, for 1 hr at room temperature
before storage at 4°C. The samples were submitted to the electron microscopy core
facility for further processing for imaging. Briefly, at the core facility, the samples
were washed and treated with 0.1% Millipore-filtered cacodylate buffered tannic
acid, postfixed with 1% buffered osmium tetroxide for 30 minutes, and stained en
bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated in
increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium.
The samples were polymerized for 2 days in a 70°C oven. Ultrathin sections were
cut in a Leica Ultracut microtome (Leica, Deerfield, IL). The sections were
subsequently stained with uranyl acetate and lead citrate using a Leica EM stainer.
The samples were examined using the JEM 1010 (JEOL Inc., Peabody, MA)
transmission electron microscope at an accelerating voltage setting of 80 kV. The
digital images were acquired using an AMT Imaging System (Advanced Microscopy
Techniques Corp., Danvers, MA).
TEM studies were conducted at the MD Anderson Cancer Center High Resolution
Electron Microscopy Facility supported by Grant CA16672 by Kenneth Dunner Jr.
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Crystal violet cell viability assay
Viability assay (crystal violet) was performed using standard procedures. Briefly,
5,000 MDA-MB-231 cells were seeded in 100 µl growth media in 96-well tissue
culture plates. They were allowed to attach overnight and subsequently treated with
the indicated doses of drugs for the indicated time points. Growth media was
removed and 50 µl of the cells were fixed and stained in 20% methanol, 0.5% (w/v)
crystal violet and washed extensively. The plates were inverted to dry out excess
water. 100 µl of Sorenson’s buffer (0.1M sodium citrate, pH 4.2 in 50% (v/v
ethanol) was added to extract the crystal violet and incubated for 1 hr and
subsequently read in a microplate reader at 570 nm absorbance.

Cell viability and proliferation assay
Cell viability was determined using the CellTiter- Blue (Promega Corp., Madison,
WI) assay. Viable cells are able to convert resazurin to resorufin which fluoresces
and can be quantified. MDA-MB-231 cells were seeded in 96-well tissue culture
plates and treated as indicated for various time points. 5 µl CellTiter Blue (Promega
Corp., Madison, WI), reagent was added and incubated at 37° C with 5% CO2 for 2
hr and read on a luminescent plate reader.

Caspase-7 activity assay
The activation of caspase 7 in MCF-7 cells was assayed using the ApoOne Kit
(Promega, Madison, WI) according to manufacturer’s recommendations.
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ATP assay
Cellular ATP was monitored using the ATPlite 1step luminescence assay
(PerkinElmer, Boston, MA) which is a luciferase based assay whereby ATP reacts
with D-luciferin and luciferase to emit light, proportional to the amount of ATP in the
cells. Briefly, cells were seeded at 5,000 cells per well in 100 µl in 96-well black
walled tissue culture plate. After overnight attachment, cells were treated as
indicated. At the experimental endpoint, the microplates were equilibrated to room
temperature and 100 µl ATPlite 1step reagent was added and placed on an orbital
shaker for 2 minutes. The plates were read in a luminescent plate reader.

DiOC6 apoptosis assay
Cells which are undergoing apoptosis have loss in the mitochondrial potential from
mitochondrial transmembrane potential, which is the due to the difference in
distribution of ions between the inner and outer membrane. This occurs early on in
apoptosis and is accompanied by the opening of the mitochondrial permeability
transition pores and release of cytochrome c. To measure changes in mitochondrial
transmembrane potential during treatment with phenothiazines, MDA-MB-231 cells
were quantified by flow cytometry using the 3,3'-Dihexyloxacarbocyanine Iodide
(DiOC6) (Invitrogen, Carlsbad, CA). Cells were seeded at 20,000 density in 3 ml
media per well in 6-well tissue culture plates. The cells were allowed to attach
overnight and treated with various concentrations of phenothiazines the following
day and incubated for the indicated time. At the experimental endpoint, both
floating and adherent cells were collected. Attached cells were collected by
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trypsinization. FBS was added subsequently to inactivate the trypsin. The cells
were washed with PBS and resuspended in fresh media. 50 nM DiOC6 and
propidium iodide (20 µg/ml in PBS with 0.1% Triton X-100, and 0.2 mg/ml RNase A)
was added and incubated for 15 minutes before analysis using the FACScan
cytofluorometer (Becton Dickinson, San Jose, CA).

Clonogenic viability assay
Colony formation assay was performed by plating MDA-MB-231 cells in 6-well
tissue culture plates at a density of 100 cells per well and allowed to attach
overnight. The following day the cells were treated with phenothiazines and DMSO
as indicated. Fresh medium was replaced every 3 days. After a 14 day treatment
period, the media was removed and the cells were fixed and stained in 20%
methanol, 0.5% (w/v) crystal violet and washed extensively. The colonies were
photographed and analyzed using the FluorChemE imaging system using the
AlphaVIEW SA version 3.2.3.0 software (Cell Biosciences Inc., San Jose, CA). The
experiment was done in triplicate and repeated three times.

Matrigel invasion assay
MDA-MB-231 cell invasion was assayed in 24-well (8 µm) Biocoat Matrigel
invasion chambers (BD Biosciences, Franklin Lakes, NJ) according to the
manufacturer's protocol. Briefly, 2.5 x105 cells were plated in triplicate in 200 µl of
RPMI in the insert compartments. The reservoir compartments of the 24 well plate
contained 5% FBS as a chemo-attractant in RPMI. Both the insert and the reservoir

32

contained the drug for the treatment condition. After incubation for 16 hr, adherent
cells on the lower surface of the inserts were fixed with 0.5% (w/v) crystal violet in
20% methanol solution for 30 minutes. The inserts were washed extensively. The
non-migrated and non-invasive cells in the upper chambers were carefully removed
with cotton tipped applicators. The migrated and invaded cells were imaged by light
microscopy. The experiments were conducted in duplicates and repeated at least
twice.

Confocal microscopy
Immunofluorescent localization and co-localization studies of MDA-MB-231 cells
were carried out an Olympus FV1000 microscope at a 100X. Images were
acquired using the Fluoview software and processed using ImageJ
(http://rsbweb.nih.gov/ij/). Briefly, MDA-MB-231 cells either transiently expressing
tf-LC3 or stably expressing GFP-LC3, were seeded in eight well chamber slides
(BD Biosciences, Franklin Lakes, NJ) at a cell density of 50,000 cells per well. Cells
were allowed to attach overnight and treated the following day as indicated. MDAMB-231 stably expressing GFP-LC3 were immunostained for LAMP2 (BD
Biosciences, Franklin Lakes, NJ) followed by staining with 568 nm (red) fluorescent
linked secondary antibody according to manufacturer’s instructions. Cells were fixed
with 4% paraformaldehyde and counter-stained with 4’-6-diamidino-2-phenylindole
(DAPI) and stored in the dark at 4C.
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Mice studies
Athymic nude female mice 20-25 g were used for in vivo tumor growth. The mice
were obtained from the National Cancer Institute (NCI, Rockville, MD) and given
food and water ad libitum under specific pathogen-free conditions in accordance to
the guidelines of the Association for the Assessment and Accreditation for
Laboratory Animal Care accredited facilities and the National Institute of Health
guidelines. All the in vivo studies protocols were carried out as approved by the MD
Anderson Animal Care and Use Committee.
Tumor implantation and treatment. For the breast tumor orthotopic model, MDAMB-231 cells were aseptically resuspended at 1 x 10 7 cells per 200 µl of
conditioned media and injected into the mammary fat pad of 5 week old athymic
nude female mice. The tumors were allowed to establish to approximately 100mm3.
Tumor volume was obtained using the formula: Tumor Volume = L x S 2/2 (where L
is the longest diameter, and S is the shortest diameter obtained using calipers).
Once the tumor reached the target volume, they were randomly allocated to 3
groups, the DMSO, phenothiazine ring, and perphenazine treatment group. The
mice were injected with 25 mg/kg phenothiazine, perphenazine, or DMSO in 100 µl
volume by intraperitoneal administration (IP) every other day for a 2 ½ and to 3 ½
weeks period when the tumor exceeded 1.5 cm (approved tumor size at the time of
the studies). At sacrifice, the mice were weighed, and tumors were excised for
immunohistological and reverse phase protein array (RPPA) studies.
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Reverse phase protein array (RPPA)
RPPA procedures for antibody staining, slide scanning, and data processing were
performed as previously described with minor modifications (121), (122). Cellular
proteins were prepared as described for western blotting prepared in denaturing
sample buffer by adding 1 part 4X SDS sample buffer (40% glycerol, 8% SDS,
0.25M Tris-HCl, pH 6.8, 10% β-mercaptoethanol) to 3 parts protein lysates prior to
heating to 95 °F for 15 minutes. Serially diluted lysates were arrayed on
nitrocellulose-coated slides (Grace Biolab) using an Aushon 2470 Arrayer (Aushon
BioSystems Inc., Billerica, MA). Each sample was robotically printed in 5 fold serial
dilutions on multiple slides including positive and negative controls prepared from
mixed cell lysates or dilution buffer, respectively, as well as multiple cell lines
incubated with and without growth factors to provide dynamic range. Each slide
was probed with a validated primary antibody followed by conjugated secondary
antibody. The signal was obtained by amplification a Dako Cytomation–catalyzed
system (123) and visualized by DAB colorimetric reaction. The slides were
scanned, analyzed, and quantified using a customized-software MicroVigene
(VigeneTech Inc.) to generate spot intensity. Each dilution curve was fitted with a
logistic model “Supercurve Fitting” developed by the Department of Bioinformatics
and Computational Biology in MD Anderson Cancer Center
(http://bioinformatics.mdanderson.org/OOMPA). This fits a single curve using all
the samples (i.e., dilution series) on a slide with the signal intensity as the response
variable and the dilution steps are independent variable. The fitted curve is plotted
with the signal intensities – both observed and fitted - on the y-axis and the log2-
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concentration of proteins on the x-axis for diagnostic purposes. The protein
concentrations of each set of slides were then normalized by median polish, which
was corrected across samples by the linear expression values using the median
expression levels of all antibody experiments to calculate a loading correction factor
for each sample.
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CHAPTER 3
________________________________________________________
Development of a High-throughput and High-content Image Based Screen for
the Identification of Modulators of Autophagy in Cancer Cells

EXPERIMENTAL RATIONALE AND GOALS

Current chemotherapeutic drugs often target rapidly dividing cells, and
consequently have toxicities against normal cells that have high proliferation rates
such as hair follicles, bone marrow, and gastrointestinal tracts.
Autophagy is an attractive mechanism to study for the development of novel drug
treatments for many reasons which include findings that some cancer cells are
dependent on autophagy for survival and proliferation. There is much interest on
how autophagy can be converted from a pro-survival mechanism to a pro-death
mechanism but the molecular mechanism by which this conversion occurs is still
poorly understood. To this end, the identification of modulators of autophagy will
allow us to study perturbations of autophagy in cancer cells and contribute to a
better understanding of potential mechanism of how autophagy modulation can lead
to cancer cell death. One important aspect in the development of therapies is the
ability to gain approval through the various stages of the clinical trials to be brought
to the clinics. Many drugs fail to pass the rigorous process due to suboptimal
pharmacokinetics and bioavailability. In order to ensure better outcome, it is
common to begin studies with screens of compound libraries of drugs and small
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chemical molecules where the bioavailability and pharmacokinetics are already
known. This increases the likelihood that findings in the lab could eventually be
brought to the clinics.
Since autophagy is a tightly regulated homeostatic mechanism which
maintains energy and protein quality in the cells, we hypothesized that
compounds which perturb the autophagy signaling network would affect
cancer cell viability. In order to test our hypothesis, we attempted to identify
modulators of autophagy using high-throughput screen that will allow us to study
perturbations of autophagy in cancer cells. We selected drugs identified by our
screen to identify where in the autophagy signaling network these drugs target to
gain insights into potential mechanisms by which perturbations of autophagy
signaling mediates cancer cell death.

Development of a high-throughput assay to screen autophagy modulators
A common starting point for identifying small molecule inhibitors of cancer
molecular targets is by high-throughput screening of diverse compound libraries.
To this end, we developed a high-throughput, high content, image based screen for
the automated image capture and analysis of autophagy perturbation by small
molecule compounds. We used stably transfected GFP linked LC3 reporter cancer
cell lines to follow the autophagic process by quantifying the number of
autophagosomes per cell (FIGURE 4) (124). For our high throughput screen, we
selected U2-OS cells on the basis of their large cytoplasmic region which allowed
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ease of automated segmentation of different subcellular regions for detection and
quantification of LC3 punctae in cells.
Using known inducers of autophagy Gleevec (Imatinib; STI571) (125), 2deoxyglucose (2-DG) (126), temozolomide (127), (127) , aminoimidazole
carboxamide ribonucleotide (AICAR) , metformin, and rapamycin (128), we set up a
prototype experiment to develop the imaging and analysis protocols and algorithms
of automated imaging and analysis of autophagosomes using the LC3 reporter.
Using this training data set, we were able to develop the parameters which correctly
identified the LC3 autophagosomal marker in each cell to quantify autophagy
upregulation which correctly measured the dose response effects of our treatments.
We also determined that Gleevec (Imatinib; STI571) and 2-deoxyglucose (2-DG)
were the strongest inducers of autophagy tested and therefore were used as the
positive controls in our screen (FIGURE 7). We validated our assay in several
prototype experiments using these algorithms and determined that our assay was
robust, and reproducible. Since most compound libraries, including the Prestwick
Chemical Library used here, are solubilized in DMSO, it was necessary to
determine the DMSO tolerance of the cells in the developmental stage of our study
and work within the identified range in our screen as well as in subsequent studies.
DMSO and untreated cells served as controls to determine basal autophagy levels
in the cells assayed.
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FIGURE 4: GFP-LC3 fluorescent reporter for autophagosomes in cells. U2OS cells were stably transfected with GFP-LC3 for identifying autophagosomes in
the cells. LC3 is diffusely distributed throughout the cell cytoplasm. Upon activation
of autophagy, it undergoes various steps of modification to ultimately be lipidated
and associated with autophagosomes, changing its diffuse pattern to a distinct
punctate or granular appearance. This change in phenotype allows comparison of
the number of punctate formations between untreated and treated conditions to
determine if the autophagic process has been modulated. Since autophagy is a
dynamic process, both increase in flux or blockage will lead to increase in number
of autophagosomes seen as punctae in the cells with the GFP-LC3 reporter.
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We captured 5 randomly selected fields in each of the 96 wells in the tissue
culture plate using the automated fluorescent microscope to ensure that more than
200 cells are assayed per condition (FIGURE 5). The optimal concentration at
which compounds in the Prestwick library would modulate autophagy was not
known at the onset of our screen. To ensure that we captured the activity window in
which the compounds modulated autophagy, we conducted our screen at 3
concentrations: 0.1 µM, 1 µM, 5 µM with each concentration on a separate 96 well
plate. Each of the plates included 4 replicates of each of our controls: non- treated,
DMSO, Gleevec, and 2-DG treated cells.
Once the images were captured, we developed and optimized an algorithm
for automated demarcation or segmentation for each of the cellular components:
cytoplasm, cell nuclei, and each punctate formation in the cell, on a cell by cell
basis. Since the compound library solvent was DMSO, we used the DMSO control
as the baseline for our screen. Any number above this threshold was used to
define a cell in which the compound treatment modulated autophagy (FIGURE 6).
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FIGURE 5: Automated image capture of each well in a 96-well microplate.
Five fields were imaged per well at 20X magnification to ensure enough cells were
sampled. The fields were selected randomly by automated software to prevent
bias.
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FIGURE 6: Automated segmentation of different cellular components. The
nuclei are identified by the Hoechst stained regions. The green fluorescent signal
was used to detect the gradient drop off for the demarcation and identification of the
cellular boundaries.
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FIGURE 7: Identification of positive controls for a high-throughput cell-based
imaged screen for modulators of autophagy. Several known modulators of
autophagy (rapamycin, AICAR, Gleevec, 2-Deoxyglucose, temozolomide, and
metformin) were assayed at different doses in U2-0S (GFP-LC3) cells at 48 hr time
points to identify positive controls and doses for screening autophagy modulators.
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RESULTS

Phenothiazines were the largest group of modulators of autophagy
Based on the 5% hit rate threshold, we identified 58 modulators of autophagy
based on changes to GFP-LC3 fluorescence distribution, from a diffuse cytosolic to
an increase in punctate or granular phenotype (APPENDIX 1). These compounds
perturb the autophagic network resulting in an increase in the number of
autophagosomes in the cells either by inducing increase in activation of autophagy
or blocking the autophagic process from going to completion (autophagic flux). The
compounds identified represented diverse groups of drugs with different
pharmacological applications. In collaboration with Drs. David Maxwell and William
Bornmann from the Department of Experimental Therapeutics, we clustered the
positive hits identified in our screen into separate groups based on their 3-D steric
structural characteristic. Ten of the 58, or 14% of the compounds identified by our
autophagy modulation screen belonged to the phenothiazine family (FIGURE 8- 9).
Phenothiazines identified as positive hits in our screen included different
phenothiazine sub-groups based on different side chain modifications of the core
tricyclic phenothiazine structure. We selected phenothiazines from each chemical
clustering based on their 3 dimensional steric structures as grouped by Dr. David
Maxwell to characterize in our follow up studies. Some of the hits identified in our
screen have been recently reported independently by other groups as modulators of
autophagy. These include camptothecin, thioridazine and colchicine (119), (129).
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FIGURE 8: Phenothiazines identified as modulators of autophagy in HTS
screen. U2-OS stably transfected with GFP-LC3 were assayed for autophagy
modulation. Panel (A) are the control conditions, NT is non-treated cells, DMSO is
the vehicle for our drugs, and Gleevec served as positive control. Our screen readout is based on diffuse GFP distribution in normal untreated cells with few punctate
formations. DMSO treatment was used to establish the basal autophagy in our
cells. Autophagy induction or inhibition results in increased punctate formations
which is indicative of autophagosome formations. Panel (B) are phenothiazines,
which have been validated by subsequent studies. Panel (C) are phenothiazines
that have not been validated in secondary assays.
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FIGURE 9: Phenothiazines identified as active modulators of autophagy by
HTS screen.
10 of the 58 compounds identified by HTS screen for autophagy modulators
belonged to the phenothiazine family. Phenothiazines used in follow up studies
were boxed in red. The parental phenothiazine compound was not in the Prestwick
Chemical Library.

47

Other studies have identified phenothiazines as modulators of autophagy using
different compound libraries (119). The overlap in the findings that phenothiazines
are modulators of autophagy by other research groups using different libraries
further strengthens our findings that phenothiazines and structurally related
compounds are robust modulators of autophagy.

Validation of chlorpromazine as modulator of autophagy in secondary assays
Of the phenothiazines identified in our screen, chlorpromazine was the oldest
and most commonly used phenothiazine in the clinics for the treatment of
schizophrenia. It is considered the prototype phenothiazine and is often used for
studies because of the abundance of clinical data available related to safety,
efficacy and dosing. We therefore selected chlorpromazine for the validation of the
findings of our primary screen and for follow-up studies. We validated our positive
hits in the U2-OS cells as well as in breast cancer cell lines with the GFP-LC3
reporter (FIGURE 10). Since our screen was conducted in the U2-OS
osteosarcoma cell line, we sought to determine if the effects of chlorpromazine
modulation were generalizable in breast cancer cells (the focus of our cancer
model). We thus conducted a dose-response study in the MCF-7 breast cancer
cells. Using the MCF-7/ GFP-LC3 stable cell line, we were able to follow the
upregulation of LC3-II in cells treated with increasing doses of chlorpromazine.
Chlorpromazine increased the punctate formations in a dose dependent manner
(FIGURE 11). This was confirmed by Western blot analysis to occur with MCF-7
endogenous LC3 proteins as well (FIGURE 12).
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FIGURE 10: Validation of up-regulation of LC3- II by compound identified as
positive hits in drug screen.

MCF-7 with stable transfection of GFP-LC3 were treated with selective compounds
identified as active modulators by the screen of autophagy modulators in a dose
gradient to validate the hits. The right top panel is a plate map of the quantified
autophagy marker of cells treated with chlorpromazine, DMSO and with the positive
controls Gleevec and Staurosporine in a dose gradient. The bottom plate map
shows cell number quantification.
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FIGURE 11: MCF-7/ GFP-LC3 Cells treated with chlorpromazine.

MCF-7 cells stably transfected with GPF-LC3 were treated with chlorpromazine for
48 hr at various concentrations. The formation of LC3-II marker as indicated by
punctate formation was monitored. The increase in percent of cells with punctate
formation above the basal level as set by the DMSO condition was used to indicate
increased punctate formation. The percent of cells with increased punctate
formation relative to DMSO is represented.
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FIGURE 12:

Western blot analysis for the formation of endogenous LC3-II.

MCF-7 cells were treated with 25 µM chlorpromazine (CPZ) for 48 hr. The level of
endogenous LC3-II was monitored by Western blot analysis.
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Chlorpromazine mediates decreased cell viability in breast cancer cells
without affecting viability of non-tumorigenic breast cells
We determined that chlorpromazine perturbed the autophagic pathway as it
increased the number of autophagosomes per cell in a dose dependent manner.
This was assessed using our automated fluorescent microscopy imaging and
analysis protocol. As part of the analysis protocol, each cell in the image field is
identified and counted. Our automated quantification of cells treated with
chlorpromazine showed a decrease in cell number in a dose dependent manner.
This decrease in cell number could possibly be due to a decrease in cell viability.
We thus sought to determine if autophagy modulation by phenothiazines decreased
cell viability. We assayed cell viability in a panel of breast cancer cells; MCF-7,
T47-D, ZR75-1, BT549, SKBr3 and a non-tumorigenic breast line MCF10-A
(FIGURE 13). These cell lines were chosen to represent different clinical sub-types
of breast cancers.
Our study showed that autophagy modulation by phenothiazines lead to
decreased cell viability in a dose dependent manner in various clinical sub-types of
human breast cancers: MCF-7, ZR75-1, T47D, BT549 and SKBR-3 cells (TABLE
2). Thus the effects of phenothiazines are generalized to different clinical sub-types
of human breast carcinomas. It has been previously reported that autophagy levels
differed between tumorigenic and non-tumorigenic cells; therefore we included the
MCF10-A cells which are a non-tumorigenic human breast cell line in order to
determine if there is a difference in phenothiazines’ effect on cell viability of nontumorigenic breast cells when compared to tumorigenic breast cells.
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Chlorpromazine treated MCF10-A did not exhibit decreased cell viability as
compared to untreated cells. Several other studies have shown that phenothiazines
mediate cell death in cancer cells while sparing normal cells (103). Zhelev et al.
showed that phenothiazines induced apoptosis in leukemic cells but not in normal
lymphocytes (130).

Chlorpromazine increases caspase-7 activation in MCF-7 cells
Viability assays measure cell viability which could be attributed either to
decreased cell proliferation or increase in cell death, we sought to determine if the
decrease in cell viability in cells treated with phenothiazine was due to cell death.
We treated the MCF-7 human breast carcinoma cells with various concentrations of
chlorpromazine and assayed apoptosis activity. MCF-7 cells have a deficiency in
caspase-3, we therefore measured the caspase-7 activity as a biomarker of
apoptotic cell death in these cells. We determined that chlorpromazine treatment
increased caspase-7 activation in a dose dependent manner in MCF-7 cells
(FIGURE 14).
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TABLE 2: Mutational status and clinical classification of breast
lines use and response to current therapies
Adapted with permission from Holliday and Speirs. Breast Cancer Res. V 13:4
(2011) (1).
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FIGURE 13: Cytoxicity of chlorpromazine in normal and breast cancer cells.
A panel of human breast cancer cell lines representing different molecular
mutations (TABLE 2) and clinical sub-types were treated with a dose gradient of
chlorpromazine for 48 hr, with a DMSO equivalent dose curve. MCF-10A is a nontumorigenic human breast line. Cell viability was measured using CellTiter-Blue.
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FIGURE 14: Treatment with chlorpromazine increased caspase-7 activation in
cancer cells.
MCF-7 cells were treated with increasing dose of chlorpromazine and assayed for
activation of effector caspase -7 after 48 hr treatment.

56

DISCUSSION
The primary aim of the studies in this chapter was to identify small molecule
modulators of autophagy to study how perturbations of autophagy affect cancer cell
viability. To accomplish this aim, we developed and executed a high-throughput
drug screen and identified positive hits. We identified 58 active modulators of
autophagy, most of which were heterocyclic compounds.
Interestingly, a group of tricyclic compounds belonging to the phenothiazine
family emerged as the largest group of positive hits in our screen. Coincidentally,
phenothiazines were also identified as active autophagy compounds by several
independent studies using different compound libraries (119), (120). This
suggested that phenothiazines are robust modulators of autophagy and therefore
the logical choice to focus of our studies of autophagy modulation in cancer cells.
Anti-tumorigenic potentials of phenothiazines in cancers were alluded to by
early epidemiologic reports that patients treated with phenothiazines had decreased
cancer incidence as compared to patients receiving other antipsychotic regiments
or compared to the general population (131), (132). Although several studies
report that phenothiazines have cancer prevention potential and antitumor activities,
the mechanism by which they mediate them have not been fully determined.
Reported targets of phenothiazines for suppression of cancer cell growth include
calmodulin (133), mitochondria (134) , P-glycoprotein efflux transporter (135), and
PDK1(136), (137). Choi et al. showed that several phenothiazines, including
chlorpromazine, fluphenazine, and thioridazine inhibited cell viability in the OVCAR3 ovarian cancer cell line. They demonstrated that phenothiazines did not mediate
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cell death through their function as calmodulin inhibitors because calmodulin
inhibitors included in their study did not have any effect on OVCAR-3 viability. In
their study, they’ve included haloperidol, a potent antipsychotic which does not
belong to the phenothiazine family, to determine if phenothiazines mediated cell
death through their antipsychotic properties. Haloperidol, like phenothiazine is a
dopamine receptor type 2 (D2) antagonist (138), (139). The authors found that
even at the highest dose of 130 µM – haloperidol did not inhibit cancer cell growth
suggesting that dopamine receptors were not phenothiazine’s target for exerting
anti-proliferative potentials in cancer cells. Since haloperidol did not inhibit cell
viability in OVCAR-3, they suggested that phenothiazines did not exert cell death
through their antipsychotic functions (136). In our screen of the Prestwick
Chemical Library, which contained haloperidol, we did not see autophagy induction
at the highest dose of 5 µM. Additional supporting evidence suggesting that
phenothiazine mediated autophagy modulation was not through their antipsychotic
or action on the dopamine receptors will be discussed in chapter 5.
Based on the findings that phenothiazines emerged from non-biased screens
from other groups as well as ours, and the finding by Choi et al. that phenothiazines
did not exert cell death through their dopamine receptor antagonist or anticalmodulin function, we will further explore how phenothiazines modulate
autophagy to mediate cancer cell death.
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CHAPTER 4
_________________________________________________________
Comparative Studies of Phenothiazines’ Effects on Cell Viability and
Tumorigenic Potentials of Cancer Cells

EXPERIMENTAL RATIONALE AND GOALS
In the previous chapter we determined that 14 % of our positive hits
belonged to the phenothiazine family. Since so many phenothiazines emerged as
active compounds in our drug screen for autophagy modulators, we aimed to
determine structure function relationship as pertaining to mediating effect on
autophagy. The parental phenothiazine core structure has been reported to have
many diverse pharmacological activities and has been used extensively to
synthesize new compounds (31). We sought to determine if the unsubstituted or
unmodified phenothiazine core structure was sufficient to modulate autophagy.
Additionally, we aimed to determine relative potencies of different phenothiazines in
modulating autophagy and their effects on cell viability.
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RESULTS

Perphenazine and chlorpromazine are the most potent modulators of
autophagy
Although we selected chlorpromazine to conduct validation assays of our
autophagy screen, we sought to determine the relative potencies of different
phenothiazines in augmenting the LC3-II levels in cancer cells. We conducted a
comparative Western blot study of several breast cancer cells treated with various
phenothiazines identified in our screen as autophagy modulators, shown here in
MDA-MB-468 cells (FIGURE 15). The selected phenothiazines: perphenazine,
chlorpromazine, chlorpyramine, promethazine, and promazine have different side
chain substitutions and represented each of the 3 sub-groups of the phenothiazine
families. The phenothiazine core ring was not in our screen but was included to
determine if the parental tricyclic structure was sufficient to exert effects on
autophagy. Immunoblotting for LC3 showed perphenazine was the strongest
inducer of LC3-II upregulation, followed by chlorpromazine. The phenothiazine
parental ring did not show an increase in LC3-II levels relative to the untreated cells
or to other phenothiazines tested, and is therefore not an active autophagy
compound. Therefore the phenothiazine parental ring will be used as the negative
control in our follow-up studies.
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FIGURE 15: Relative potencies of different phenothiazines in modulating
autophagy and inducing apoptosis.
MDA-MB-468 cells were treated for 24 hrs with different phenothiazines to
determine relative strength of autophagy modulation and inducing apoptosis. Cells
were treated at different concentrations of perphenazine (10 µM, 20 µM, 40 µM) and
20 µM of several phenothiazines identified in our drug screen: Chlorpromazine
(CPZ), Chlorpyramine (CPY), Promazine (PMA), and Phenothiazine core ring
(PTZ). The relative levels of LC3-II, and cleaved PARP were determined by
Western blot analysis. All samples were on the same Western blot, and extraneous
non-pertinent information was removed for clarity.
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Perphenazine and chlorpromazine are the most potent phenothiazines in
reducing cell viability in a dose dependent manner
The results of our Western blot study demonstrated that perphenazine and
chlorpromazine were the most effective up-regulators of LC3-II levels. This
upregulation of LC3-II correlated with an increase in cleaved PARP in the
phenothiazine and chlorpromazine treated cells. Promazine showed increase in
LC3-I and LC3-II levels but did not show a corresponding increase in cleaved PARP
level. In order to have a quantitative analysis of the relative potencies of the
different phenothiazine in mediating cell death, we conducted a dose response
study using the following selected drugs: perphenazine, chlorpromazine,
chlorpyramine, promethazine, promazine and the core phenothiazine ring (FIGURE
16). Cells were treated for 48 hr and viability was assessed using CellTiter-Blue
(Promega). Of the phenothiazines studied, perphenazine was the most cytotoxic
phenothiazine, followed by chlorpromazine. Promazine decreased viability in this
assay. Further studies would be needed to determine the reason for the failure of
promazine to induce PARP cleavage (FIGURE 15) and to decrease cell number
(FIGURE 16). The parental phenothiazine structure had no cytoxicity relative to the
DMSO treated cells. Based on these findings, we selected perphenazine,
chlorpromazine, and the phenothiazine parental ring structure to conduct further
studies.
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FIGURE 16: Comparative analysis of phenothiazines in decreasing cell
viability.
MDA-MB-231 cells were treated with increasing doses (0, 5, 10, 20, 30, 40, 60, 120
µM) of DMSO and phenothiazines for 48 hr. PTZ: phenothiazine core ring
structure, PPZ: Perphenazine, CPZ: Chlorpromazine, CPY: Chlorpyramine, PMZ:
Promethazine, PMAZ: Promazine.
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Perphenazine increases LC3 II expression and PARP cleavage in a time
dependent manner
In comparing the relative potencies of various phenothiazines from our
screen, we established that perphenazine was more effective in decreasing cell
viability in MDA-MB-231 cells than chlorpromazine and other phenothiazines
included in our study. We sought to determine if perturbation of autophagy by the
strongest phenothiazine tested correlated with decreased viability through
apoptosis. In the previous chapter, we determined that chlorpromazine induced
apoptosis in the MCF-7 cells by measuring caspase-7 activation, and demonstrated
that the concentration dependence of induction of LC3-II and caspase cleavage
induced by perphenazine were similar. Here, we assessed activation of apoptosis
by monitoring the status of poly (ADP-ribose) polymerase (PARP) (140) in MDAMB-231 cells treated with 20 µM perphenazine at 24 hr and 48 hr (FIGURE 17).
We conducted immunoblotting using an antibody specific for the cleaved PARP
protein; this antibody detects the cleaved form of PARP, but not the full length
PARP. We determined that perphenazine caused a time dependent increase in
cleaved PARP levels which correlated with the increase in LC3-II protein level. This
suggests that perturbation of autophagy by perphenazine led to apoptotic cell death
in MDA-MB-231 cells, or alternatively, that a common effector was upstream of both
processes.

64

.

FIGURE 17: Perphenazine treated cells have increased cleaved PARP and
LC3-II in a time dependent manner.
MDA-MB-231 cells were treated with 20 µM perphenazine or grown under the cell
starvation condition of serum and glucose free medium for 24 hr and 48 hr. Cells
treated with perphenazine exhibited increased cleaved PARP levels as well as LC3II levels in a time dependent manner.
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Phenothiazine mediated cell death is attributed in part by apoptosis
Based on our previous studies, which showed phenothiazines induced
apoptosis as measured by caspase-7 activation in MCF-7 cells, and cleavage of its
substrate, PARP in MCF-7 and MDA-MB 231 cells respectively, we next sought to
determine if apoptotic cell death was the main mechanism by which cells treated
with perphenazine underwent cell death. We treated several types of cancer cells
with perphenazine or co-treated with the wide spectrum caspase inhibitor, Z-VAD,
at concentrations shown to inhibit apoptosis in other systems, and determined that
inhibition of caspase pathway partially abrogated cell death mediated by
perphenazine. This suggests that perphenazine mediates cell death partially
through apoptosis, but cell death was also mediated through a different mechanism
(FIGURE 18).
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FIGURE 18: Perphenazine mediated decreased cell viability is contributed by
apoptosis.
Several cancer cell lines were treated with 20 µM perphenazine or co-treated with
the wide spectrum caspase inhibitor ZVAD (100nM) for 48 hr. (Shown here, the U2OS cells). Cell viability was measured by crystal violet viability assay.
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Perphenazine mediates apoptotic cell death through loss of transmembrane
mitochondrial potential
At the early stages of apoptosis, the mitochondrial proton gradient across the
mitochondria is lost. Loss or collapse in membrane potential is frequently used as a
marker of apoptosis. 3, 3′-dihexyloxacarbocyanine iodide (DiOC6) is a green
lipophilic cationic fluorochrome used to measure the mitochondrial trans-membrane
potential. When used with PI, live cells only fluoresce green. PI dye is nonpermeable in live cells. Dead cell have damaged plasma membrane that leads to
the uptake of PI dye and thus fluoresce red. Using fluorescent activated cell
sorting, we identified the subpopulation of dead cells. We conducted a time course
of MDA-MB-231 cells treated with 20 µM perphenazine (our most potent
phenothiazine). At the 24 hr time point only 6.6% of the cells were dead, with an
increase to nearly 17% at the 48 hr timepoint, and to a final cell death of nearly 70%
at 72 hr (FIGURE 19).
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FIGURE 19: Measure of loss of mitochondrial potential in PPZ treated cells.
MDA-MB-231 cells were treated with 20 µM perphenazine for 24 hr, 48 hr, and 72
hr to determine a cell death timeline. Cell death was measured using relative PI
levels as described in materials and methods. DMSO was the vehicle control.
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Perphenazine and chlorpromazine induce an increase in double membraned
vacuoles as determined by EM
Christian de Duve first observed and used the terms ‘autophagy’ and
‘autophagic vacuoles’ to describe the process of autophagy using electron
microscopy in 1963 (141). More than 50 years later, electron microscopy continues
to be the gold standard in determining the presence of autophagosomes (142)
(143). We used transmission electron microscopy (EM) to confirm our Western blot
analysis and fluorescent microscopic studies which showed accumulation of
autophagosome markers LC3-II. We selected MDA-MB-231 breast carcinoma cells
of the triple negative clinical subtype (ER-/PR-/HER2-), to conduct our follow-up
studies, and later in vivo animal studies. This subtype of breast cancer has the
poorest clinical outcome (144). We treated the cells with 20 µM of phenothiazine
core ring (PTZ), chlorpromazine, perphenazine (PPZ), or the DMSO equivalent to
determine the presence of autophagosomes by ultrastructure analysis of the cells
through EM. Perphenazine was also treated with 10 µM in addition to the 20 µM for
dose response assessment. In comparing the potency of the different
phenothiazines in increasing the number of autophagosomes per cell, we
determined that the parental phenothiazine core ring (PTZ) had no effect, while
chlorpromazine (CPZ) had modest effect, and perphenazine (PPZ) was the most
potent in upregulating the number of vacuolar vesicles containing condensed cell
materials, as indicative of autophagosomes (FIGURE 20). EM data showed that the
parental phenothiazine ring structure was not sufficient to potentiate the
accumulation of autophagosomes.
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FIGURE 20: Ultrastructural analysis of autolysosomes by EM. MDA-MB-231 cells were treated with
the parental phenothiazine ring structure (PTZ), chlorpromazine (CPZ), perphenazine or DMSO for
24 hr for ultrastructural analysis for the presence of autolysosomes. Ultrasctructures are labeled as: N
nuclei, Mt mitochondria, arrows autolysosomes

Perphenazine was the most potent phenothiazine in decreasing cellular ATP
in cancer cells
Since autophagy is a catabolic mechanism which sequesters cytoplasmic
contents and organelles to generate substrates for generation of energy in the cells,
agents which perturb this pathway could potential affect cellular energy. We
therefore sought to determine the energy status of cells treated with phenothiazines.
MDA-MB-231 cells treated with the 20 µM chlorpromazine, perphenazine and
phenothiazine core ring for 24 hr and cellular levels of ATP was assayed (FIGURE
21). Perphenazine was the most potent in decreasing cellular ATP, followed by
chlorpromazine, while the phenothiazine core ring had no effect on cellular ATP
levels. The decrease in ATP levels in cells treated with PPZ was observed at the
effective dose which mediated decreased cell viability and upregulation of
autophagosomal number as assessed by our EM study.
One key function of autophagy is maintenance of cellular energy levels.
Through its catabolic activity, it provides amino acids and lipids for production of
acetyl-CoA for the TCA cycle for the generation of ATP. Disruption of autophagy
impairs mitochondrial function, potentially resulting in production of reactive oxygen
species (ROS) and causing mitochondrial damage. Additionally, impaired
autophagy leads to toxic buildup of defective mitochondria in the cells, resulting in
cell death.
Zelev et al. proposed that the selective cytotoxicity of phenothiazine in
lymphoblastic leukemia is due to inhibition of mitochondrial DNA polymerase and
decreased ATP production. Sachlos et al. noted that mitochondria DNA
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polymerase (although present in lymphoblastic leukemia cells) is present in normal
lymphocytes and therefore may not be the reason for decreased ATP production
(145). Previous studies have proposed that the mechanism whereby
phenothiazines decrease the ATP levels in the cells were mediated by inhibition of
calmodulin. However, Ruben et al. reported that this is not the case based on their
findings that in phenothiazines still mediated decrease in ATP in mitochondrial
extract lacking calmodulin. Instead, they proposed that phenothiazines mediated
decrease in ATP production through inhibition of the mitochondrial ATPases (146).
Since tumors are rapidly proliferating, they have higher metabolic demands
than normal cells, and more sensitive to energy perturbations than normal cells.
This could potentially explain the selective toxicity of phenothiazine against cancer
cells while sparing normal cells, seen in our study of breast cancer cells and the
non-tumorigenic MCF10-A cells in earlier in this chapter.
Studies in mice have shown that chemoagents which deplete cellular ATP
enhance the therapeutic efficacy of antitumor agents (147), therefore it is important
to further explore the mechanism behind phenothiazines’ ability to decrease cellular
ATP.
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FIGURE 21: Perphenazine decreases cellular ATP. The cellular ATP status was
determined in MDA-MB-231 cells treated with 20 µM perphenazine,
chlorpromazine, and the phenothiazine core ring structure for 24 hr. Previous
timecourse studies of cell death showed that cell death did not occur until after 48 hr
at the 20 µM dose used.
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Perphenazine decreased the invasive potentials of cancer cells
Aggressive cancer cells must digest through the basement membrane in
order to disseminate to distant sites to form metastatic tumors. We used the
Boyden chamber migration assay to quantitate the inhibitory potential of
perphenazine on cell invasion requiring enzymatic degradation of the Matrigel
matrix (148), (149). The coating on the membrane mimics the in vivo extracellular
basement membrane, and functions as a barrier to the passage of non-invasive
cells. The chambers consist of 8 µm micro-porous Matrigel coated membranes to
assay tumor cell invasion for assessment of the anti-metastatic potential of
phenothiazines.
Invasive potentials of MDA-MB-231 cells were determined after 16 hr
treatment with different doses of perphenazine, phenothiazine core ring, or DMSO
(FIGURE 22). Previously, our timecourse study for cell death determined that at
24h, MDA-MB-231 cells treated with 20 µM PPZ only had 6.6% decreased cell
viability. We therefore assayed the invasive potential of MDA-MB-231 cells after 16
hr drug treatment to ensure that any observed reduction in number of invaded cells
through the Matrigel was due to inhibition of invasive potential rather than cell
death.
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FIGURE 22: Effects of perphenazine on the invasive potential of cancer cells.
MDA-MB-231 cells were treated for 16 hr with various doses (1 µM, 10 µM, and 20
µM) of perphenazine (PPZ) and assayed for invasive potential through a Matrigel
matrix as compared to untreated, DMSO treated controls or 20 µM phenothiazine
core ring structure (PTZ Ring). Experiment was conducted in duplicate, and
repeated three times.
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Perphenazine and chlorpromazine decreased the clonogenic potentials of
cancer cells.
We measured the cell viability, with dye reduction assays, of cells treated
with different phenothiazines, which assessed the number of metabolically active
cells. Cancer cells must be able to proliferate and form colonies of hundreds and
thousands of cells in order to form a tumor or to metastasize. In an in vitro
clonogenic assay, cells are plated at a low density to assess the ability of single
cells to proliferate and form a colony (150), (151). Using this assay, we determined
the effectiveness of perphenazine in reducing the clonogenic potential of MDA-MB231 cancer cells. We compared the relative potency of the core phenothiazine ring,
chlorpromazine, and perphenazine as anti-clonogenic agents (FIGURE 23). Our
clonogenic survival study showed that treatment with the core phenothiazine ring
alone did not mediate decrease in clonogenic potential of the cells at our highest
dose of 20 µM. Both CPZ and PPZ inhibited the clonogenic potential of MDA-MB231 cells at 10 µM.
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FIGURE 23: Effects of different phenothiazines on clonogenic potential of
cancer cells. MDA-MB-231 cells were seeded at 100 cells/ well in a 3 ml volume of
media in 6-well tissue culture plates. The cells were treated with different
concentrations (5 µM, 10 µM, and 20 µM) of phenothiazine ring, chlorpromazine,
and perphenazine to assess the relative potencies of the different phenothiazines in
inhibiting clonogenic potential in MDA-MB-231 cells.
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DISCUSSION
Understanding the biological effects of phenothiazine modulation of
autophagy is important in understanding how phenothiazine can be used within the
context of cancer treatment in a clinical setting. We and others have shown that
treatment of cancer cells with different phenothiazines mediate cancer cell killing in
a dose and time dependent manner. Since several phenothiazines were identified
as positive hits in our screen, we sought to determine if these activities were
inherent to the core phenothiazine structure itself. The parental phenothiazine ring
is a pharmacologically active drug with many reported activities; however, we
determined that without additional modification and substitution, it was not sufficient
in mediating the measured antitumorigenic effects in the cell lines assessed.
Perphenazine and chlorpromazine have been reported to be the most cytotoxic
phenothiazines relative to other phenothiazines in different cell lines, including
glioma and fibroblasts (103). Our comparative studies showed that perphenazine
was more potent than chlorpromazine in inducing of apoptotic cell death through
caspase activation. This is consistent with findings by Kanzawa et al. that side
chain substitution on the parental phenothiazine which contain a piperazine
heterocyclic ring conferred higher antitumor activity than aliphatic chain substitution
(152) (FIGURE 24).
Our timecourse study of cell death showed that PPZ caused loss of
mitochondrial membrane potential at 72 hr. We therefore conducted our invasion
assay at 16 hr to ensure that the decreased number of invasive cells were in fact
due to inhibition of invasive potential as opposed to decreased cell viability. In
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addition to decreasing cell viability by apoptosis through caspase activation with
subsequent PARP cleavage, perphenazine and chlorpromazine attenuated the
cells’ invasive capacity as measured by invasion through the Matrigel membrane of
the Boyden invasion chambers. Decreased invasive potential of MDA-MB-231
treated cells could be attributed to the fact that phenothiazines mediate decrease in
cellular ATP. Chlorpromazine has previously been observed to both decrease
cellular ATP and inhibit the ability of tumor cells to generate ATP (153). Decrease
in cellular energy can impact several cellular processes which are important for
cancer cell survival. Because cancer cells are rapidly growing and are under
metabolic stress, they are more sensitive to energy perturbations that normal cells.
Autophagy degrades macromolecules and organelles to provide amino
acids, fatty acids which are used to produce ATP through the tricarboxylic acid
(TCA) cycle. Abedin et al. reported that 45-50% of mitochondria were co-localized
with autophagosomes after cells were treated with activators of autophagy (74).
This suggests that mitochondria were sequestered within the autophagosomes.
Functional autophagy regenerates ATP through degradation of macromolecules
and organelles. The decrease in cellular ATP in cells treated with phenothiazines
suggests that phenothiazines disrupted autophagy.
Additionally, perphenazine and chlorpromazine inhibited the ability of MDAMB-231 single cells to form colonies at 10 µM as assessed by clonogenic potential
assays. This inhibition of the ability for the cancer cells to form colonies is
especially important in context of in vivo cancer formation as it prevents single cells
which have shed to distant sites from establishing new tumors. Although
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perphenazine and chlorpromazine mediated their decreased viability effects at
doses of 20-30 µM at 48 hr treatment, they were effective in mediating the inhibition
of clonogenic potential at a lower dose of 10 µM. This difference could be attributed
to the fact that the measure of clonogenicity is clearly different than that of viability
measure. Viability assays measure metabolically active, viable cells, without
distinguishing if these viable cells are capable of forming colonies from single cells.
In all our measures of inhibition of tumorigenic potential of PPZ and CPZ,
PPZ was more potent relative to CPZ. Interestingly, this correlates with the
antipsychotic potentials of these drugs, with PPZ being more potent, and the dose
which it is prescribed to patients is one forth to one sixth of that prescribed for CPZ
(154). The difference in relative potencies of PPZ and CPZ may be attributed to the
side chain substitution on the phenothiazine tricyclic core structure. Although
phenothiazines are amphiphilic cations and can readily interact with cellular
membranes (155), the side chain substitution on the parental ring influences how
easily they cross cellular membranes. Perphenazine’s piperazine substitution is
more lipophilic than chlorpromazine’s aliphatic substitution and thus perphenazine
can better interact with cellular membranes and more effectively cross through them
to reach their cellular targets.
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FIGURE 24: Substitution on phenothiazines affects lipophilic activity.
Aliphatic substituted phenothiazines are less soluble than phenothiazines
with piperazine substitution.
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CHAPTER 5
_________________________________________________________
Identification of Perphenazine’s Target in the Autophagy Signaling
Network

EXPERIMENTAL RATIONALE AND GOALS

An increase in LC3-II and the appearance of autophagosomes in cells
following treatment with phenothiazines could occur as a consequence of an
increase in autophagosome formation, blocked autophagosome turnover, or
blocked autophagic flux (156). We sought to determine the status of autophagic
flux by using p62 which is a normally long lived protein that is targeted for
degradation in the final steps in the autophagy pathway. Thus p62 is often used for
as indicator of autophagic flux. Cells growing in nutrient replete conditions have low
levels of p62; treatments which block the autophagy pathway increase cellular
levels of p62 (157). We used pharmacologic inhibitors of the autophagy signaling
network to assess where along the pathway perphenazine targets to upregulate
LC3-II. Many inhibitors targeting different proteins in the autophagy signaling
network are non-specific and have other cellular targets. We therefore, used RNA
silencing and MEFs cells with knockout of the autophagy gene Atg5 to complement
our studies.
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RESULTS

Perphenazine treatment blocks autophagic flux and increases p62 and LC3-II
In order to understand how perphenazine perturbs the autophagy signaling
pathway, we determined the expression status of the core regulators of the
autophagy machinery in MDA-MB-231 cells before and after treatment with
perphenazine.
We first determined if autophagy is induced or blocked. p62 levels were
used to determine autophagic flux. MDA-MB-231 cells subjected to perphenazine
(PPZ) treatment for 48 hr had increased p62 and LC3-II protein levels (FIGURE 25).
Increased p62 levels in the cells treated with PPZ indicate that autophagic flux is
blocked, likely contributing to the increased LC3-II levels in the cells.
Next, we sought to identify targets along the autophagy signaling pathway that
could explain the effects of PPZ on autophagic flux. Induction of autophagy
involves the activation of the class III PI3K/Vps34/Beclin 1 complex (158), and LC3II recruitment to autophagosomal membrane is Atg5 dependent (159).
Immunoblotting for Beclin 1 and Atg5 showed that the Beclin 1 and Atg5 levels were
not altered following perphenazine (PPZ) and phenothiazine (PTZ) treatment,
suggesting that these proteins are not the primary targets of phenothiazines in
MDA-MB-231 cells. Additionally, this suggests that cells treated with
phenothiazines may undergo autophagy through alternative autophagy pathways
that are not dependent on changes in Beclin 1 and Atg5 levels.
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FIGURE 25: Effects of perphenazine treatment on the autophagy signaling
pathway. MDA-MB-231 cells were treated with perphenazine, phenothiazine ring
at 10 µM and 20 µM and compared to the non-treated, serum and glucose free
starved condition for 48 hr for the analysis of changes in protein levels of the
autophagy signaling network by Western blot. Immunoblotting was carried out with
antibody against: Beclin 1 (BCN), Atg5, p62, LC3-I/II, ERK2 (loading control).
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Pharmacological inhibition of the different steps of the autophagosomal
signaling pathway elicit potential sites of action of phenothiazines
In order to determine where perphenazine affects the autophagosomal
pathway to cause increases in LC3-II protein levels and to block autophagy flux, we
used pharmacological inhibitors known to target different steps of the autophagy
pathway. We targeted multiple steps from the formation of the autophagosome to
the later stage where fusion of the autophagosome with the lysosomes occurs
(FIGURE 26). We treated MDA-MB-231 cells with 3-MA, a class III PI3K inhibitor,
which inhibits the nucleation of autophagosomes (160), Bafilomycin A1 (Baf A1), an
H+ ATPase inhibitor which can increases the pH of lysosomes and decreases the
fusion of autophagosomes with lysosomes (161), and the E64d protease inhibitor,
which inhibits lysosomal proteases, thus decreasing protein degradation in the
lysosome (162), (163).
Inhibition of the autophagosome nucleation step with 3-MA in MDAMB231
cells did not alter the ability of PPZ to increase LC3-II levels. This is unexpected as
the initial phases of autophagy are through to be required for processing of LC3 to
LC3-II. This could be due to incomplete inhibition of the autophagosome nucleation
step by 3-MA or alternatively could potentially be explained by autophagy activation
occurring through an alternative autophagy pathway, known as the non-canonical
autophagy pathway(164).
As expected, inhibition of autophagosomes and lysosomes fusion by Baf A1,
lead to augmentation in LC3-II levels in MDAMB231 cells in the absence of
phenothiazines, due to blockade of LC3-II degradation. Co-treatment with PPZ and
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Baf A1 slightly augmented LC3-II levels compared to either agent alone. LC3-I was
converted to LC3-II as seen by decreased LC3-I in the presence of PPZ and Baf A1
as compared to Baf A1 treatment alone. E64D, a protease inhibitor that blocks
protein degradation in the autophagosome and lysosome was sufficient to increase
LC3-II alone, a process that was modestly augmented by addition of PPZ. These
studies are compatible with phenothiazines altering the later stages of autophagy at
the level of the lysosome, or potentially acting upstream of lysosomal function.
In examination of the levels of autophagy regulators Beclin 1 and Atg5, we
determined that PPZ treatment only caused a modest decrease in Atg5 levels, and
no detectable changes in Beclin 1 levels as compared to the untreated MDA-MB231 cells. These effects were insufficient to explain the effects of phenothiazines on
LC3-II or autophagy flux.
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FIGURE 26: Pharmacologic inhibition of core regulators of the
autophagosomal pathway. MDA-MB-231 cells were treated with 20 µM
perphenazine with and co-treated with each of the inhibitors targeting different steps
of the autophagy core signaling pathway; 3-MA (5 mM), E64d (10 µM), and
Bafilomycin A1 (50 nM) for 24 hr.
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siRNA knockdown of autophagy core signaling regulators
Since chemical inhibitors of the autophagy pathway are not always specific
and may have additional cellular targets, it was necessary to confirm the above
observations by genetic inhibition of the various steps of autophagy using RNA
silencing (165).
We complemented our pharmacological inhibition study of the various steps
of autophagy with knockdown of target genes essential for autophagy using short
interfering RNA (siRNA). The experimental controls were untreated cells, the cells
treated with the transfection agent (mock), RISC-free siRNA (RF), and serum and
glucose free medium (SGF). Beclin 1 is required for the formation of the
phagophore and the Atg12-Atg5 complex is required for maturation of
autophagosomes and in particular formation of LC3-II. Beclin 1 knockdown with
siRNA in MDA-MB-231 cells showed that despite marked Beclin 1 silencing, the
ability of perphenazine (PPZ) to increase LC3-II levels was not ablated. We next
sought to determine if PPZ mediated its effects through Atg5-Atg12 step of
autophagy regulation. Using siRNA targeting Atg5 and Atg12, we silenced the
expression of both proteins and treated the cells with PPZ. Again, RNAi knockdown
of Atg5 and Atg12 did not abrogate the increase in LC3-II levels following PPZ
treatment (FIGURE 27). Thus similar to 3-MA treatment above, blocking the
autophagosome formation steps with RNAi knockdown of Beclin 1, Atg5 and Atg12.
The lack of effect of inhibition of the early steps in the autophagy cascade on LC3-II
formation was puzzling as these are proposed to be obligatory steps in the classical
autophagy cascade described in the introduction. This raises the possibility that the
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3-MA and the knockdown of autophagy pathway members was not sufficient to
completely block initiation of the classical pathway. In the presence of block of
autophagy flux by phenothiazines, sufficient autophagy initiation occurred to result
in accumulation of LC3-II and p62. Alternatively, it is possible that cells underwent
autophagy activation through a non-classical or non-canonical autophagy pathway.
Together, our studies of the effects of PPZ on components of the autophagy
cascade are most compatible with PPZ mediating its effects on later steps in the
autophagy pathway and thus blocking autophagy flux rather than autophagy
initiation. One possibility is that PPZ may potentially target the autophagosome and
lysosome fusion step to inhibit lysosomal degradation of autophagosome contents.
This would increase both LC3-II and p62 are they are both degraded following
autophagosome-lysosome fusion. We therefore proceeded to examine the fusion of
the autophagosomes with the lysosomes and lysosome function.
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FIGURE 27: Inhibition of autophagy signaling network fails to inhibit
accumulation of LC3. MDA-MB-231 cells were transfected with siRNA targeting
Beclin 1 or Atg5 and 12 for 48 hr followed with treatment with perphenazine for 24
hr.
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Effects of phenothiazines on cell viability is independent of Atg5 activation
Our RNA knockdown approach to silence the activity of different core
regulators of the autophagy signaling network determined that increased LC3-II
levels were not dependent of the classic early steps in upregulation of autophagy.
Since knockdown of the Atg5/Atg12, or Beclin 1 genes may not been completely
effective, we also used autophagy deficient cells, mouse embryonic fibroblasts
(MEFs) lacking Atg5 genes, Atg5 -/- MEFs to complement our study. Recently, it
was reported that MEFs lacking Atg5-/- were be able to undergo autophagy through
an Atg5 independent pathway. When starved or treated with etoposide, these cells
were able to form vacuoles which did not have LC3-II lipidation (166). We have
confirmed that PPZ treated MEFs Atg5 double knockout cells had LC3I which were
not converted to LC3-II (data not shown). Using these classic autophagy pathway
deficient cells, we aimed to confirm that the decrease in viability mediated by PPZ is
not dependent on activation of the classis autophagy pathway. Wild type MEFs and
Atg5 -/- mutant cells were treated with increasing concentrations (5, 10, 20, or 40
µM) of PPZ for 48 hr and cell viability was assayed (FIGURE 28). PPZ treatment
decreased cell viability in both cell lines, but there were no significant differences in
cell viability based on the cells’ ability to activate autophagy. This suggests that
PPZ mediated decrease in cell viability is not dependent of Atg5 activation. We've
previously shown in chapter 3 (FIGURE 13) that chlorpromazine did not have any
cytotoxic effect on the non-tumorigenic human breast cells MCF10-A up to 40 µM.
Here, however, wt MEFs, non-tumorigenic fibroblast cells have marked decrease in
cell viability when treated with perphenazine. The differences in sensitivity to
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phenothiazine treatment between these cell lines may be due to MCF-10A being a
human cell line, whereas the MEFs cells were of mice origin. Another potential
underlying difference is that MCF-10A cells are breast cells whereas MEFs are
fibroblast cells. The level of basal autophagy in each of the cell types may also
contribute to final outcome on cell viability upon drug treatment.
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FIGURE 28: Perphenazine mediated decrease in cell viability is independent
of Atg5 activity. Mouse Embryonic Fibroblast (MEFs) wild type, or Atg5 double
knock-out (Atg5 -/-) cells were treated with 5, 10, 20, or 40 µM of perphenazine
(PPZ) or DMSO for 48 hr. The cell viability was assayed by crystal violet assay.
The data is represented as percent relative to the untreated control cells.
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Perphenazine causes non-productive autophagy at the autophagosomal
lysosomal fusion step of the autophagy cascade
To determine if phenothiazines affect lysosomal degradation of proteins by
lysosomes at the final step of autophagy, we utilized a plasmid construct of LC3
tandemly expressed with red fluorescent protein (RFP) and green fluorescent
protein (GFP), or tf-LC3. The tf-LC3 constructs are commonly used to study the
fusion step of autophagosomes to lysosomes. GFP and RFP have different
sensitivity towards the acidic lysosomal environment with GFP being more sensitive
to lysosomal pH than RFP (61). Hence, autophagosomes show both RFP and GFP
signals, but upon fusion with lysosomes, the GFP signal is attenuated and only the
RFP signal remains. MDA-MB-231 cells were transiently transfected with the
tandemly expressed RFP and GFP LC3 plasmid (tf-LC3) and subjected to treatment
with 20 µM perphenazine (PPZ), DMSO, Baf A1, or EBSS medium (for starvation
condition) (FIGURE 29). DMSO served as the control to show the basal autophagy
condition in the cells. Under basal conditions, the RFP signal will be dominant as
LC3 exists mostly in the cytoplasmic form with little being delivered to the
lysosomes (FIGURE 29). Starvation upregulates autophagy and results in the
delivery of autophagosomal bound LC3 to the lysosomes for degradation. EBSS
medium was used as the starvation condition to show upregulation and completion
of autophagy. In this condition, it would be predicted that the GFP signal would be
attenuated leaving mainly the RFP signal, which is what was observed (FIGURE
29). Baf A1, the lysosomal proton pump inhibitor, disrupts lysosomal pH and
inhibits the fusion of autophagosomes with lysosomes, therefore leaving GFP intact.
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As expected, in Baf A1 treated cells, both GFP and RFP signals remained intact as
indicated by the dominant yellow color in the merged image (Figure 29). When
MDA-MB-231 were treated with 20 µM PPZ for 24 hr both the RFP and GFP signals
persisted resulting in a mimic of the effects of Baf-A1. There are three possibilities
as to why both the RFP and GFP signals remained intact: impairment of maturation
of autophagosomes into autolysosomes, aggregation of autophagosomes, or
successful fusion but defective lysosomal enzyme function. Defective lysosome
function, either as a consequence of non-functional proteases or loss of acidification
would result in their inability to degrade proteins and an accumulation of the yellow
signal. Together the data, particularly when combined with accumulation of LC3-II
and p62, argues that PPZ blocks the degradative step of autophagy, resulting in
non-productive or abortive autophagy.
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FIGURE 29: tf-LC3 showing perphenazine treatment blocks LC3 degradation.
MDA-MB-231 cells were treated with 20 µM perphenazine (PPZ), DMSO, or 50 nM
Baf A1 for 24 hr, and EBSS treatment for 4 hr. tf-LC3 is a tandemly expressed red
fluorescent protein (RFP) and green fluorescent protein (GFP) to the LC3. Scale
bar, 50 µm.
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Perphenazine causes lysosomal volume expansion Based on the above
findings that GFP signals of the tf-LC3 construct persisted in perphenazine treated
cells, we sought to determine if autophagosomes co-localized with lysosomes to
deliver their cargo to autolysosomes for degradation. We assessed the sub-cellular
localization of these organelles by confocal microscopy using MDA-MB-231 cells
stably transfected with GFP-LC3 in conjunction with the LAMP-2 antibody, a marker
of lysosomes (FIGURE 30). In control cells, lamp 2 stained vesicles whereas LC3
was cytosolic. In PPZ treated MDA-MB-231 cells both LC3 and LAMP-2 were
located in vesicles which are some cases overlapped. However, the
autophagosomes and lysosomes has distinctly different appearance as compared
to untreated cells. PPZ increased LC3 amount, as well as increased LC3 puncta
size in the cells; indicative of increased in both number and size of
autophagosomes. Additionally, PPZ caused expansion in lysosomal volume
compared to untreated counterparts. These findings suggest that PPZ, at least in
part, targets lysosomes prior to their fusion with autophagosomes. Indeed,
perphenazine and chlorpromazine have been reported to induce increase in
lysosomal vacuole expansion in lung carcinoma cells (167). Recently, Funk et al.
studied drugs containing amine groups and their effect on lysosomal volume. They
observed that imipramine, a weakly basic amine, which is similar to the weakly
basic amines in phenothiazines, increased the lysosomal volume 4-fold (168).
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FIGURE 30: Perphenazine treatment causes lysosomal volume expansion
(immunofluorescence). MDA-MB-231 cells stably expressing GFP-LC3 were
treated with 20 µM perphenazine (PPZ) for 24 hr. The cells were immunostained
with lysosomal marker LAMP-2 (red). Perphenazine treated cells exhibited
lysosomes (red) with enlarged surface areas (indicated by the arrows) as compared
to the untreated cells.
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Perphenazine causes expansion in autophagy vacuoles and lysosomal
number and size
We sought to determine whether the expansion of autophagosomal and
lysosomal size and number observed in the fluorescent immunohistochemistry
study could also be detected by EM, which is considered the “gold standard” for
analysis of organelle structure including autophagosomes, autolysosomes and
lysosomes. MDA-MB-231 cells were previously shown to have increased
autophagosomal vacuoles containing cellular debris when treated with
chlorpromazine and perphenazine in chapter 4. Perphenazine treatment also leads
to extensive increase in the number of lysosomes and autophagosomes (FIGURE
31). Phenothiazines are weakly basic amines, which preferentially localize to
lysosomes. Amines have been reported to induce vacuolization which can take up
to 30% of the cell volume (169). More detailed discussion of mechanism of action
of lysosomotropic agents will be undertaken in the next section.
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FIGURE 31: Perphenazine treatment causes autophagosomal vacuole
expansion (EM). Ultrastructural study of MDA-MB-231 cells treated with 20 µM
perphenazine (PPZ) for 24 hr showed extensive vacuolization –seen as increase in
the number and size of lysosomes and autophagosomes.
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DISCUSSION

In this chapter, we have shown that perphenazine blocked autophagic flux as
measured by increase in p62 levels in cells. This blockage would be expected to
result in the previously observed increase in LC3-II levels. Since LC3-II
accumulation could be attributed to aggregated autophagosomes, inhibition of
fusion of autophagosomes to lysosomes, or inhibition of LC3-II autolysosomal
degradation, we systematically determined the status of autophagy regulators for
each step of the autophagy pathway.
We determined that pharmacological inhibition of autophagy initiation with
3-MA did not decrease LC3-II levels in cells treated with perphenazine. In contrast,
inhibition of acidification of lysosomes and the activity of lysosome proteases
increased LC3-II levels independent of the presence of phenothiazines. Because
autophagy inhibitors may not be fully effective in inhibiting their target and are
known to have non-specific targets beyond the autophagy signaling network, we
complemented this approach by systematically blocking key steps of the autophagy
signaling pathway using siRNA. siRNA knock-down of regulators of early steps of
autophagosomal formation, Beclin 1, Atg5 and Atg12, did not abrogate the effects of
perphenazine on LC3-II accumulation. This could happen due to insufficient
knockdown to completely inhibit pathway initiation. Indeed, since LC3-II
accumulation did not occur on PPZ treatment of Atg5 knockout MEFs, inadequate
knockdown with the siRNA may indeed be the case. Alternatively, PPZ treated cells
may undergo autophagy through an alternative autophagy activation process that is
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not Beclin 1, Atg5 or Atg12 dependent. Autophagy which is independent of Beclin 1
and Vps34 is known as non-canonical autophagy, as opposed to Beclin 1
dependent autophagy known as canonical autophagy. Scarlatti et al. showed that
breast cancer cells treated with resveratrol activated autophagy and underwent cell
death that was independent of Beclin 1, and therefore insensitive to 3-MA inhibition
(170).
We used classical autophagy incompetent cells, Atg5 double knock-out
MEFs to determine whether the effects of perphenazine were dependent on Atg5mediated autophagosome formation. Nishida et al. have demonstrated that MEFs
Atg5 -/- were able to form autophagosomes when treated with etoposide, thus
providing evidence of yet another alternative autophagy pathway with Atg5
independent formation of autophagosomes. However these autophagosomes do
not contain LC3-II. Cell death mediated by PPZ was not dependent on autophagy
activation through Atg5. In order to confirm if MEFs which are deficient in Atg5
undergo autophagy when treated with PPZ, EM studies, or other approaches
independent of LC3-II formation will need to be conducted.
However, these studies have major consequences in interpretation of the
mechanisms by which phenothiazines cause cell deaths. As indicated in previous
chapters, cell death, LC3-II accumulation and blockage of autophagic flux
demonstrated similar structure function and concentration dependencies. Thus, we
hypothesized that the block in autophagic flux was the cause of death. However, as
PPZ causes death in cells lacking Atg5 and unable to undergo classic autophagic
flux, it is possible that the cell death induced by PPZ is, at least in part, independent
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of the block in autophagic flux. Alternatively, at least in MEFs cells, a non-classic
autophagy pathway may contribute to cell death.
Using co-localization studies using the lysosomal marker LAMP-2 with LC3
autophagosomal marker, we were able to determine that the autophagosomes and
the autolysosomes co-localized. We determined that PPZ disrupted lysosomal
function and autophagic flux as the GFP signal was not attenuated. GFP is
sensitive to low pH. Since its signal was not attenuated, this suggests that
perphenazine increased lysosomal pH or ablated the functions of its hydrolases.
Another possible explanation for the persistent GFP signal is that the
autophagosomes did not fuse with the lysosomes to deliver the GFP linked LC3 for
degradation. Lysosomal fusion to autophagosomes requires and acidic lysosomal
pH. Thus in future mechanistic studies more direct assays of the accumulation of
phenothiazines in lysosomes, effects on the pH of lysosomes, enzyme activity of
lysosomal hydrolases and the formation of autolysosomes would need to be
completed.
Lysosomes degrade cellular macromolecules through hydrolases, which are
delivered as precursors by the trans-Golgi system to the lysosomes. There are over
50 lysosomal hydrolases which are activated through autocatalytic activity or
processing by other proteases in the lysosomes. These require acidic pH in order
to be activated. Lysosomal pH ranges from 4.5 to 5 as compared to the cytosolic
pH of 7. The difference in pH is maintained by H+ ATPases which pump protons
from the cytosol to the lysosomal lumen (171).
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Drugs or compounds which accumulate in the lysosomes are defined as
lysosomotropic drugs (172). Lysosomotropic drugs have a lipophilic and basic
component. The lipophilic component allows them to interact with the phospholipid
membranes of cellular organelles such as lysosomes. Lipophilic weak base
compounds accumulate more effectively than hydrophilic weak bases (173). Due to
the pH difference between the cytosol and lysosomal lumen, weak bases move
down their concentration gradient and accumulate in the lysosomes, often several
orders of magnitude greater than the surrounding cellular environment (172), (174).
In the cytosol, they are uncharged and cross freely into the lysosomes (175). Once
inside the lysosomes they are protonated and become trapped due to the acidic
lysosomal pH. This phenomenon was first described as ion trapping by de Duve
and is also known as lysosomal trapping (172), (176). The basic compounds raise
the lysosomal pH, disrupting the functions of the lysosomal hydrolases (177).
Another means by which amphiphilic amines increase the lysosomal pH is through
the inhibition of H+ ATPases (178).
Recently, several phenothiazines, including chlorpromazine, promethazine,
and thioridazine, were identified as lysosomotropic compounds through a drug
screen by Nadanaciva and colleagues (129). The authors noted that many of the
compounds identified in their screen had two common characteristics: basic pKa
values ranging from 6.6 and 11, and a lipophilic component. Of the drugs identified
by this study, chloroquine, and Gleevec (Imatinib) were previously reported to affect
autophagy. Chloroquine (CQ) is a well-known autophagy inhibitor and a
lysosomotropic drug that neutralizes the positive charge of the lysosomes, raising

105

their pH to abrogate their ability to fuse with autophagosomes (179). CQ has been
reported to induce lysosomal volume dilation in retinal pigmentation epithelial
(ARPE) derived cells (180) and other cells (181), (182).
Additionally, many compounds identified in the screen were antipsychotics
of the phenothiazine and non-phenothiazine family. This was attributed to the fact
that antipsychotics are lipophilic and effectively cross the blood brain barrier (183).
Daniel et al. reported that many psychotic compounds including desimapramine,
piperazine, piperidine undergo lysosomal trapping (184), (185). Lysosomal trapping
could therefore be a plausible explanation as to why many of the positive hits
identified in our screen included other, non-phenothiazine, antipsychotics as well.
Nadanaciva et al. proposed that lysosomotropic agents could disrupt the
lysosomal degradative function by raising its pH, in doing so, inhibit the final step
autophagy. Bafilomycin A1 and chloroquine are commonly used to inhibit
autophagy and are described as lysosomotropic agents. Baf A1 inhibits the H +
ATPase, which functions to acidify the lysosomes, this leads to an accumulation of
autophagosomes in the cell due to the lysosomes’ inability to degrade them (186).
Drugs which are more lipophilic cross the lysosomal membrane more easily
than hydrophobic drugs. Chlorpromazine belongs to the aliphatic subclass of
phenothiazines, having carbon chain substitutions and is not as lipophilic as
perphenazine which has a piperazine substituted side chain. Perphenazine is
therefore able to cross the cellular membranes more easily than chlorpromazine to
reach its targets. The pKa value of phenothiazine (PTZ), chlorpromazine (CPZ),
and perphenazine (PPZ) are: 0, 9.30, and 7.94 respectively (187). Weakly basic
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amines with pKa values close to 8, in their unionized state freely cross membranes
(141). PPZ’s pKa value of 7.94 is the closest to 8 relative to CPZ and to PTZ and
therefore would be expected to cross more easily into the cell and then into
lysosomes. Lipophilic compounds which are weakly basic bases cross the
lysosomal membranes freely and become trapped in the lysosomes through
becoming ionized. In their ionized state, they are unable to cross back out of the
lysosomes where they remain trapped and raise the lysosomal pH (FIGURE 32).
The relative potencies of PTZ, CPZ, and PPZ in mediating cell death could be
attributed to their lysosomotropic attributes such as ease of crossing membranes
and ability to increase lysosomal pH. In addition to being better able to permeate
membranes to reach the lysosomes, PPZ has 3 sites where it can be ionized, as
compared to CPZ, which only has 2 sites, thus, it could be more potent in increasing
the lysosomal pH.
Morissette et al. have shown that the concentration of bases which
accumulate in the cells correlated with the extent of vacuolization observed.
They’ve also found that the same drug caused different degrees of vacuolization in
different cell types (188). The results of comparative studies of phenothiazines in
the previous chapter demonstrated that PPZ was more potent in upregulating LC3II, p62, and cell death than CPZ and the phenothiazine parental ring (PTZ). This
suggests that the effects of phenothiazines on cancer cell viability may be due to
lysosomal trapping as PPZ’s physiochemical properties allows it to more effectively
cross cellular membranes and increase lysosomal pH, consequently blocking
autophagy at the lysosomal stage. This failure to complete the autophagy process,
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sometimes described as abortive autophagy could then lead to cancer cell death.
However, it is important to point out that PPZ induces death in ATG5 knockout
MEFs. Thus the death induced by phenothiazines is not absolutely dependent on
the classic autophagy pathway and, in MEFs, could be due to initiation of nonclassical autophagy or interference with lysosomal function directly.
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FIGURE 32: Phenothiazines contain weak amine base groups and undergo
protonation in acidic environments. Phenothiazines have amines groups and
are weakly basic. At neutral pH, they exist as non-ionized (unprotonated) species
and cross freely through biological membranes but become ionized in acidic
compartments such as lysosomes. Once ionized (protonated), they cannot cross
back out of the lysosomes into the cytosol and become trapped. This phenomenon
is known as ion trapping, or lysosomal trapping.
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CHAPTER 6

Determination of the Effects of Perphenazine on Cancer Cell
Signaling Pathways in vivo and in Other Cancer Cell Lines

RATIONALE AND EXPERIMENTAL GOALS
Although there are large numbers of in vitro studies of phenothiazines and
cancer, in vivo studies are still lacking. Human tumor xenografts are routinely used
to evaluate antitumor effects of drugs in a metabolically intact organism for the
study of the effects of drugs on tumor versus normal tissues (189). In order to
ascertain if perphenazine mediated abortive autophagy which resulted in cell death
in vitro could be observed in vivo, we conducted an MDA-MB-231 xenografted
mouse study.
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RESULTS

In vivo study shows PPZ treatment elevated p62 protein expression is
accompanied by increased cleaved PARP protein expression levels
We injected MDA-MB-231 cells into the mammary fat pads of 5 week old
female athymic nude mice. The tumors were allowed to establish to a palpable size
for one week. Once the tumor reached a minimum volume of 0.5 mm3, the mice
were randomly separated into 3 treatment groups: DMSO, PTZ ring, and PPZ
treated group. Intraperitoneal (IP) drug treatment was delivered on alternate days
with a starting dose of 25 mg/kg. This dose was ill- tolerated by the animals; the
mice showed extreme lethargy and sedation through 4-5 hr post-treatment.
Consequently, we decreased the dosage several times over the course of the next
two weeks to a final dose of 2 mg/kg. At the conclusion of our study, we did not
observe tumor mass reduction in the animal model, potentially due to being unable
to deliver adequate doses.
Although the xenografted tumors did not show differences in growth rate or
tumor volume among the treatment groups, we sought to determine if our drug
treatment had any effect on the established tumors at the molecular level.
Specifically, we sought to determine if the signaling effects on autophagy observed
by in vitro studies were replicated in vivo. We therefore collected the xenografted
tumors at sacrifice for frozen tissues preparation as well as for paraffin embedded
preparations for our follow-up studies. Protein lysates were prepared from the
frozen samples for studies using the reverse phase protein array (RPPA) platform
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whereby we measured upregulation or downregulation of proteins commonly
involved in regulation of cancer signaling. The analysis of the xenografted tumors
showed that a subset of the tumors from PPZ treated mice had increased p62
protein levels (FIGURE 33). Tumors which expressed increased p62, also had
increased cleaved PARP level (indicative of apoptotic cell death). This is consistent
with the results from our in vitro studies where increased LC3-II formation and p62
levels correlated with increased cleaved PARP levels in a dose and time dependent
manner. A more detailed study of the protein expression profiles comparing the
responders against the tumors which did not respond to PPZ treatment could yield a
better understanding of which additional signaling pathways, apart from the
autophagic signaling pathway was targeted to bring forth cell death.
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FIGURE 33: In vivo study of signaling events altered with perphenazine
treatment. MDA-MB-231 xenografted tumors of two drug treatment groups were
compared: perphenazine (blue color) and phenothiazine core ring (teal or light
blue). The groups were clustered and 3 clear groups emerged. Group A consisted
of 4 core phenothiazine ring treated and 4 perphenazine treated mice. Group B
showed phenothiazine treated mice have increase in p62 and increase in cleaved
PARP, which were consistent with in vitro studies. Group C consisted of 7
perphenazine treated mice and one phenothiazine core ring treated mouse. Mice in
group C did not have increase in p62 nor increase in cleaved PARP.
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RPPA study of perphenazine treatment of human cancer cells
harboring different mutations
Cancer cells harbor mutations which influence how they respond to different
therapeutics. We sought to determine if certain mutational background sensitizes
cancer cells to PPZ treatment by assessing its effects on a panel of 16 human
cancer cells of different tissue origins, including breast, ovarian, osteocarcinoma,
prostate, melanoma and a non-tumorigenic breast line (TABLE 1). Cell lines
selected included different mutational status commonly found in patient clinical
samples to ensure that our findings would be clinically relevant. For example,
breast cancer lines used in our studies have been shown by gene expression
microarrays to have the same transcriptome profiles as patient samples and to be
appropriate models for breast cancer studies (190). We used RPPA to measure
protein levels and phosphorylation status of proteins in the cell lysates to measure
upregulation or downregulation of signaling pathways commonly deregulated in
cancer. A comprehensive time course study of cells treated with PPZ was
conducted to generate protein expression profiles for each cell line (APPENDIX 2).
We compared the effects of PPZ treatment on protein expression across the 17 cell
lines using the 48 h timepoint of our study.
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Perphenazine treatment elevates p62 levels accompanied by increased cell
death proteins and decrease autophagy proteins in several human cancer cell
lines
We studied the expression profiles of protein levels in our panel of cancer
cells in response to 48 hr perphenazine treatment (FIGURES 34-35). We
determined that p62, a long lived protein targeted for degradation during late stages
of autophagy, is elevated in many of the cells lines, but to varying degrees. This is
in agreement with our Western blot analysis of MDA-MB-231 and other cell lines
which showed perphenazine treatment increased p62 levels. Our RPPA data also
showed increase in the apoptotic cell death protein (caspases) levels in cell lines
with the highest p62 levels.
Interestingly, in our RPPA panel, the cell lines most sensitive to
perphenazine treatment – with the strongest increase (red) and decrease (green) in
protein level relative to DMSO condition were two cell lines of melanoma origin:
SKMEL-5 and WM-35. SKMEL-5 showed impaired or down-regulated autophagy
as seen by p62 increase, indicating blocked autophagic flux. Additionally, SKMEL-5
exhibited the most decrease in 2 important autophagy genes, Beclin 1 and Atg7.
More importantly, the decreased autophagy pathway activation was accompanied
by increase in levels of cell death pathway regulators caspase-3 and caspase-7.
These findings are consistent with reports that melanoma cancers harbor activating
Ras mutations which lead to autophagy addiction for survival, thus rendering them
sensitive to PPZ inhibition of autophagy relative to other types of cancers.
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SKMEL-5 also exhibited the strongest upregulation of BiP (immunoglobulin
heavy chain binding protein), also known as GRP78, which is a marker of UPR
activation. UPR activation is mostly a cytoprotective mechanism, but sustained
activation leads to apoptosis activation (191). Our RPPA study suggests that
perphenazine inhibited autophagy seen as increased in p62 levels and mediated
cell death through caspase activation. Perphenazine mediates abortive autophagy,
blocking the final step of autophagy by inhibiting lysosomal function. We
hypothesize that in doing so, it causes a bottleneck upstream, leading to
accumulation of aggregated proteins. This places stress on the ER system, leading
to activation of the UPR system. Our lab has previously shown that abortive
autophagy activates ER stress which consequently causes cell death (30).
MSH2 and MSH6 are two proteins involved in DNA mismatch repair (MMR).
Expression levels of both proteins are decreased in nearly all cell lines treated with
perphenazine. This suggests that PPZ treatment impairs DNA repair in the cells.
This is in concordance with previous studies which showed that phenothiazines
potentiate the cytotoxic effects of DNA damage by bleomycin in vivo studies of high
grade gliomas (192).
Our RPPA results showed that in our panel of breast cell lines, the MDA-MB231 cells were one of the least sensitive cells to perphenazine treatment. This
offers a potential reason as to why our MDA-MB-231 xenograft studies did not show
tumor size regression or shrinkage. The breast cancer cell line most sensitive to
PPZ treatment was SKBR-3; it had similar upregulated or downregulated protein
profile as the SKMEL-5 cells. Based on these results, the SKBR-3 cell line may
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have been a more appropriate line to initiate in vivo studies with. The nontumorigenic breast line, MCF10-A, treated with PPZ had lower p62, caspase-3,
caspase-7 and BiP protein levels relative to the tumorigenic cell lines. These
results were consistent with the fact that tumor cells have higher metabolic needs
and are under low levels of ER stress. When these tumor cells are faced with
additional stress stimuli from chemoagents or radiation therapy, they undergo more
intensive ER stress, and upregulate UPR to try to bring the cells back to
homeostatic levels. Although UPR is an adaptive response to support cell survival
in adverse conditions, sustained UPR activation leads to the activation of apoptosis
thus results cell death (193). The waterfall graphs showed MCF-7 cells had low
caspase-3 expression at the baseline, in agreement of the fact that MCF-7 cells
have non-functional caspase-3 through base pair deletions (194).
SKMEL-5 cells which had the strongest upregulation of p62, caspase-3 and
caspase-7, shows downregulation of autophagy genes Beclin 1, Atg7, and p760SK.
p706SK is an effector of the mTORC1 signaling pathway that is required for
autophagy (195),(196).
Due to time constraints, only a few of the strongest up and downregulated
proteins were examined. More detailed studies of the time course of the proteins
which showed the strongest upregulation or downregulation in our RPPA studies by
Western blot analysis to confirm our findings will be necessary to gain in depth
understanding of how PPZ perturbs the global protein signaling in the cells.

117

FIGURE 34: Protein expression
profiles of cancer cells treated with
perphenazine
Human cancer cell lines of different tissue
origins were treated with 20 µM
perphenazine and normalized to DMSO.
Cell lysates were processed on a reverse
phase protein array (RPPA) and stained
for antibodies to each of the indicated

proteins and phospho-proteins by the
Functional Proteomics Reverse Phase
Protein Array Core Facility.
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FIGURE 35: Waterfall graphs showing proteins with the strongest level of

upregulation or downregulation due to perphenazine treatment. Proteins

which showed the strongest increase or decrease in expression levels in our

heatmap representation of our data were graphed to exhibit correlation in cell line

DISCUSSION
One of the aims of the studies in this chapter was to determine if the in vitro
findings of previous chapters could be observed in vivo. MDA-MB-231 xenografted
into nude mice did not show tumor mass reduction, but analysis of protein levels of
the different sub-group of tumors showed that some tumors responded to PPZ
treatment. In these tumors, PPZ did block autophagy, as seen in elevated p62
levels compared to the group which consisted mostly of the core parental group, our
negative control in the experiment. The tumors with elevated p62 levels had
corresponding increase in cleaved PARP levels, indicative of cell death. These
observations suggest that in vitro mediated anti-tumorigenic potentials of PPZ
mediated through autophagy manipulations could be translated in vivo. Thus PPZ is
a viable candidate for development of cancer therapy. The lack of growth inhibition
in the mice may be due to it being relatively insensitive to phenothiazines even in
vitro.
Mutational status or genetic background of cancer cells can potentially
determine the outcome of autophagy inhibition (197). Although the focus of the
studies of phenothiazines in the earlier chapters of this thesis were conducted in
breast cell line MDA-MB-231 cells, we wanted to determine if certain mutational
status or different types of cancers were more them sensitive to autophagy
inhibition by perphenazine. Our study of a panel of 17 human cell lines of diverse
mutational status and cell lineages showed that each cell line displayed different
protein activation profiles (APPENDIX 2). Examination of the protein expression
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status of the 48 hr treatment across cell lines showed that PPZ inhibited autophagy
nearly all the cancer cells and mediated cell death through caspase activation.
Different degrees of sensitivity to PPZ treatment was observed in the
different cell lines. SKMEL-5 and WM-35 melanoma cell lines were the most
sensitive to perphenazine treatment as compared to the non-tumorigenic breast and
other cancer cell lines in the study. This is in line with Motohashi and colleagues’
findings that phenothiazines preferentially accumulate in melanoma tissues, and
were more effective against these types of cancers (91). Others have also reported
antitumor activity of phenothiazines in melanoma cells in in vivo mice studies (135).
Additionally, both SKMEL-5 and WM-35 have B-Raf mutations, which confirm
findings from John Weinstein’s group. The Weinstein lab examined drug activity in
context of mutational status of the NCI-60 cell lines and found that melanoma cells
with the Ras pathway B-Raf gene mutation were sensitive to phenothiazines (102).
These computational modeling findings were confirmed experimentally. Since
melanoma cells have 40-60% activating B-Raf, and more than 90% of B-Raf
mutations in melanoma cancers are V600E mutations, where valine to glutamine
mutation occurred at codon 600 (V600E), phenothiazines could potentially be
effective against these cancers. PLX4032 (vemurafenib) is a V600E B-RAF
inhibitor currently approved for patients with melanoma (198). Combining PPZ with
this inhibitor may potentially have synergistic effects to enhance the efficacy of both
drugs.
Differences in toxicity to PPZ treatment as seen in relative upregulation
levels of caspases could also be attributed to the different mutational status of cells
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such as Ras driven cancer cells. These cells have been shown to be highly
dependent on autophagy for survival. Inhibition of autophagy in these tumor cells
result in synthetic lethality conditions which enhance cell death potentials of the
drugs. However, this is not universal as MDA-MB-231 which has both RAS and
BRAF mutations is relatively insensitive to phenothiazine.
In addition to mutational status of different cancer cells which may contribute
to their sensitivity to perphenazine treatment, the number of lysosomes in different
cell types could also contribute to differences in sensitivity. More comprehensive
studies of the data is necessary in order to map out other pathways that are
affected by perturbation of autophagy by perphenazine. Based on the findings in
our previous chapters, we generated a proposed model of how perphenazine
mediates cancer cell death (FIGURE 36). Through its properties as a weakly basic
amine, perphenazine (PPZ) diffuses passively through cellular membranes to travel
down its concentration and pH gradient into lysosomes. PPZ becomes ionized in
the lysosome’s acidic environment and remain trapped inside the lysosomes by a
phenomenon known as lysosomal trapping. Since PPZ is converted from the unionized form after reaching the lysosomes, the concentration difference between the
cytosol and the lysosomes is maintained. This difference functions as a driving
force for diffusion of PPZ, allowing it to reach concentrations which are several fold
higher in the lysosomes relative to the cytosol. In doing so, they also cause osmotic
pressure to increase. Consequently, the lysosomes expand to relieve the
increasing pressure which is as seen in dilated vacuoles observed by EM and by
fluorescent microscopy. By raising the lysosomal pH, PPZ disrupts lysosomal

122

functions by inactivating lysosomal hydrolases which require low pH and prevent
lysosome fusion to autophagosomes. By disrupting these lysosomal functions, PPZ
prevents autophagy from going to completion, disrupting autophagic flux which
results in abortive autophagy. Abortive autophagy has been shown by our group to
activate ER stress (30).
In blocking autophagy’s degradative step, PPZ causes increase in unfolded
and aggregated protein concentrations in cells. The ER, which is also involved in
protein quality control in the cell, becomes overwhelmed and undergoes ER stress
resulting in the activation of UPR. Sustained activation of UPR activates apoptosis
and results in cell death (193).
Additionally, by inhibiting the degradative step of autophagy, PPZ blocks the
cells’ ability to recycle damaged organelles, and cytoplasmic contents for energy to
sustain proliferation and survival, thus leading to cell death.
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FIGURE 36: Model of proposed mechanism of perphenazine mediated cancer
cell death.
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CHAPTER 7

OVERVIEW, FUTURE DIRECTIONS
Many current therapies target apoptosis or programmed cell death type I
(PCD I) as a mechanism of cell death. Taxanes commonly used to target apoptosis
are paclitaxel and docetaxel, which bind to tubulin and stabilize the microtubule
bundles and impairs mitosis (199). This causes cell cycle arrest and initiates
apoptosis (200). Cancer cells develop resistance to these drugs by point mutations
on the tubulins, or by expressing different isoforms of tubulins to impair taxane
binding (201), (202). Other cancers acquire resistance by overexpressing Pglycoprotein efflux pumps to decrease drug concentration in the cells, thus
decreasing their efficacy. Because autophagy is also known as programmed cell
death type II (PCD), it became an attractive target to explore for cancer drug
development. We therefore sought to understand how autophagy which is
commonly known as a cell survival mechanism could be converted to a cell death
mechanism in cancer cell.

The two main aims of this dissertation were: 1) to understand how
modulation of autophagy in cancer cells affects their viability, and 2) to
determine whether autophagy could be targeted for cancer therapy.

In order to accomplish the first aim, we conducted a HTS of small molecules
to identify active autophagy modulators. We characterized the largest group, the
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phenothiazines, and determined that in perturbing autophagy, they induced cancer
cell death in a panel of breast cancer cells. We systematically examined different
steps of the autophagy pathway through genetic and pharmacological inhibition as
well as cells deficient in autophagy genes to determine where phenothiazines
exerted their effect to mediate cell death. We determined that phenothiazines
blocked the degradative step of autophagy by targeting lysosomes. We showed
perphenazine disrupted the lysosomal phenotype, as indicated by marked increases
in lysosomal volume as observed by immunofluorescence study and EM.
Phenothiazines are weakly basic amines and accumulate in lysosomes through a
mechanism known as lysosomal trapping. Once they reach the low pH in the
lysosomes, they become ionized, gaining a proton, and raise the lysosomal pH to
disrupt both the lysosomal hydrolase functions as well as the fusion step between
autophagosomes and lysosomes. This effectively blocks autophagy flux, causing
abortive autophagy.
Differences in the relative potencies of the phenothiazines in modulating
autophagy and inhibiting proliferation correlated with how easily these cross the
cellular membranes to reach their targets. Substitution on the parental ring
influence solubility, and without any substitution, the parental ring had no autophagy
activity. In comparing chlorpromazine with perphenazine’s relative activity on
autophagy and cell viability, perphenazine was more potent in mediating these
effects. This could be attributed to chlorpromazine’s aliphatic substitution being less
lipophilic than perphenazine’s piperazine substitution. Additionally, the pKa value of
perphenazine is closer to 8, the optimal pKa value which allows amines to cross
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freely across membranes. Perphenazine’s ability to better induce abortive
autophagy than chlorpromazine is likely through its ability to better disrupt
lysosomal function based on its physiochemical properties which permitted ease of
crossing through membranes to act as a lysosomotropic agent. Perphenazine was
more potent than chlorpromazine in mediating antitumor activity in MDA-MB-231
cells and effectively decreased cancer cell invasion, and cellular ATP in these cells.
Therefore, in aim one, we’ve determined that perphenazine mediated cancer cell
death as a process which was associated with disrupting autophagy at the final
step, by targeting lysosomal functions.
The coordinate effects of different concentrations on different structures of
autophagy and cell death was consistent with the processes being potentially
causal. However, the ability of perphenazine to decrease the growth of wild type
and Atg5 knockout MEFs at similar concentrations suggests that classical
autophagy which requires Atg5 may not be a prerequisite for perphenazine
mediated death. However, non-classical forms of autophagy have been
hypothesized. These may contribute to the ability of perphenazine to induce cell
death. Additional studies will be necessary to elicit the mechanisms responsible for
perphenazine mediated cell death.
The second aim of this dissertation was to determine if autophagy could be
targeted for cancer therapy. In order to determine if the in vitro results of our
studies would be applicable in vivo, and determine if our findings could eventually
be brought to the patients, we conducted human xenograft MDA-MB-231 studies.
We found that a sub-group of tumors responded to perphenazine treatment,
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showing autophagy was inhibited as seen in the increased levels of p62. This
inhibition was accompanied by cell death as indicated by increased cleaved PARP
levels. Although we were not able to show tumor regression, our study provided us
with a starting point for dosing, and design of future experiments.
In chapter 6, we also aimed to determine if certain mutations or types of
cancers were more sensitive to autophagy inhibition by perphenazine. Through our
study of a panel human cancer cell lines, we’ve determined that melanoma cancer
cells (SKMEL-5 and WM35) with B-Raf mutations were more sensitive to autophagy
inhibition by perphenazine relative to other types of cancers, including breast
cancers. This confirms findings by the Weinstein lab that melanoma cells with
specific B-Raf mutations having increased sensitivity to phenothiazines. Our
findings were also consistent with findings from the White lab that Ras activated
cancers were more sensitive to autophagy inhibition due to autophagy addiction.
However, MDA-MB-231 cells which have both Ras and B-Raf mutations were
comparatively less sensitive to the effects of perphenazine. Thus, other context
dependent events contribute to sensitivity. Our reverse phase protein array (RPPA)
study also showed cells that had the most decreased autophagy genes which were
accompanied by highest increased expression of caspase proteins. Additionally,
these cells also had upregulated expression of the ER chaperone BiP/GRP78
protein, indicative of unfolded protein response activation (UPR), known to induce
apoptosis. Bip protein expression level was decreased in MCF10-A, the nontumorigenic breast cell line which did show not decrease in cell viability when
treated with chlorpromazine in chapter 2. Together, these findings suggest that

128

perphenazine induced abortive autophagy, which causes cancer cell death while
sparing normal cells.
The potential utility of phenothiazines in the clinic as an anti-cancer treatment
is underscored by findings from the studies presented here as well as findings
previously reported by other groups. Pre-clinical studies have shown that
phenothiazines are antitumorigenic against different types of cancers (131), (137),
(203). Recently, a study showed that phenothiazines target cancer stem cells
without killing normal cells, thus providing additional supporting evidence that
phenothiazines are cytotoxic against tumor cells with limited toxicity to normal cells
(145). Phenothiazines are attractive agents to explore in context of cancer
therapies because in addition to many reported antitumorigenic potentials, they are
relatively inexpensive and are widely available. Additionally, we’ve shown that
perphenazine exerted the anti-proliferative activities at concentrations which are
within reported plasma levels (2-36 µM) of patients treated with phenothiazines for
psychotic conditions such as schizophrenia (130) (145).
Autophagy inhibition by phenothiazines could have clinical utility as
numerous studies provide evidence that activation of autophagy by cancer cells
decreases therapeutic potentials of many current cancer therapies (204), (205).
Examples of how autophagy activation attenuates cancer treatments include glioma
cells treated with temozolomide (TMZ) that activated autophagy and induced
resistance to TMZ’s cytotoxic effects. When Baf A1 was combined with TMZ to
inhibit autophagy, the cells underwent apoptotic cell death (127). Cancer cells
subjected to ionizing radiation (IR) undergo cell cycle arrest and autophagy
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activation. Inhibition of autophagy by Baf A1 or 3-MA with IR treatment rendered the
cells more sensitive to IR, resulting in more extensive DNA double-strand breaks
than IR treatment alone (206). Human neuroblastoma cells treated with paraquat,
an inducer of active oxidative stress, resulted in autophagy activation. When
autophagy activation was inhibited with 3-MA, apoptotic mediated cell death was
accelerated (207). Cancer cells treated with the DNA-damaging agent, doxorubicin,
activate autophagy, attenuating doxorubicin efficacy; inhibition of autophagy by
various agents led to increased cancer cell toxicity (208). Breast cancer treatment
with tamoxifen, an estrogen antagonist, induces autophagy; inhibition of autophagy
enhanced tamoxifen’s efficacy (209), (210). Mefloquine toxicity in neuroblastoma
cells is enhanced when autophagy is inhibited (211). Inhibition of autophagy
impairs the cells’ ability to repair DNA damage induced by radiation therapy or
anticancer drug camptothecin or etoposide (topoisomerase I and topoisomerase II
inhibitors), thus enhancing their cytotoxic potentials (212). Autophagy also confers
resistance to dasatinib treatment in B-cell chronic lymphocytic leukemia (213).
These are only few examples where autophagy activation interferes with anticancer
treatments. Pre-clinical studies have shown phenothiazines enhanced efficacies of
cancer drugs (108), (107). Perphenazine could potentially be introduced in
combination therapies with the above anticancer treatments to inhibit autophagy
and increase efficacy of these cancer treatments.
Presently, in the United States alone, there are more than 30 clinical trials
involving combination of chemotherapy with the inhibition of autophagy with
chloroquine (CQ) or hydroxychloroquine (HCQ) (199), (214). Chloroquine and
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hydroxychloroquine inhibit lysosomal acidification, blocking the degradation step of
autophagy. Since our studies suggest perphenazine exert its effects on autophagy
in a similar manner as CQ, and may also act to increase pH in lysosomes this
provides evidence that perphenazine could have real clinical potential as an
inhibitor of autophagy and can be implemented with treatments which have been
shown to have increased efficacy when combined with CQ to inhibit autophagy.
Autophagy is a complex mechanism with contradictory roles that are context
dependent. Since autophagy has many important physiologic functions in the cells,
manipulation of this process can impact normal cells adversely. It is therefore
necessary to target key differences between cancer and normal cells to selectively
affect tumor cells and limit toxicities to normal cells. Cancer cells have high energy
requirements along with low oxidative phosphorylation to sustain their rapid growth.
For these cancers, inhibition of autophagy could be a good strategy for cancer
treatment. Our findings that cells treated with perphenazine have decreased ATP
levels can have several consequences in the cancer cells, all of which leads to cell
death. Cells need ATP to survive, and in conditions where there is nutrient
deprivation, cancer cells will upregulate autophagy to survive the stress. Since
cancer cells have a higher need for energy than normal cells in order to sustain their
rapid growth, this may allow selective cancer cells killing with relatively low toxicity
to normal cells.
Inhibition of autophagy must be approached with caution as dysregulation of
autophagy has consequences in neurodegenerative diseases like Alzheimer’s
disease, Huntington, and Parkinson’s disease due to toxic-intracellular protein

131

aggregates (215). Therefore, short term treatment or low dose treatment of
autophagy inhibitors may be warranted to prevent acute accumulation of proteins
which could cause neurodegenerative diseases. In this regard, perphenazine offers
the advantage of having had a long history as an antipsychotic where its safety is
already established. Our studies showed that autophagy inhibition and cell death
occurred within achievable plasma levels, thus further supporting the utility of
phenothiazines as an antitumor agent. Since the clinical trials for chloroquine are
ongoing and the results are not yet available, it is important to continue to explore
other inhibitors of autophagy (62).

Together, these findings support previous

studies that phenothiazines are viable compounds to pursue in the development of
combination therapy for therapeutic strategy against cancers, cells with activating
Ras or Raf mutations may be selectively sensitive, providing a potential biomarker.

Future Directions
We have demonstrated that phenothiazine may target lysosomes, disrupt
their function which is associated with expansion of lysosomal volume. In our
tandemly expressed GFP and RFP LC3 protein study, we determined that GFP
persisted in PPZ treated cells which is consistent with increased lysosomal pH
which prevented degradation of GFP by lysosomal hydrolases. It will be necessary
to confirm the lysosomal pH changes mediated by phenothiazines through pH
sensitive lysosomal probes.
Our xenograft studies showed that PPZ mediated autophagy inhibition in a
subgroup of tumors which showed increased cleaved PARP levels. Analysis of
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immunohistological samples of xenografted tumors could lead to better
understanding of differences in response to perphenazine among different tumor
groups of our in vivo experiment. Information gained would provide knowledge of
how to design future experiments for animal studies for perphenazine for the
development of therapeutic intervention against cancer.
Our comprehensive timecourse study of perphenazine treatment in 16
human cell lines (15 tumor, and 1 non-tumorigenic cell line) was a huge
undertaking. It involved numerous months for the execution of the timecourse
study, preparation of the RPPA samples for printing on the micro slides, followed by
months of the data processing. We’ve examined the 48 hr timepoint as the
endpoint of our study here to gain insight into which type of cancers were most
sensitive to perphenazine, and determined which proteins were most strongly
upregulated or downregulated as a consequence of perphenazine treatment.
Comprehensive analysis of the data was not possible due to time constraints, and
the complexity is beyond the scope of this study. It is included here in APPENDIX 2
to show that beyond perturbing autophagy, perphenazine also impacts other
signaling networks. This comprehensive study is complex and requires use of
signaling models to map out perturbations of signaling networks. More in depth
analysis of the data could offer insights into the early and late signaling events
which could be targeted in combination with inhibition of autophagy in order to allow
development of more effective therapeutic strategy based on mutational status and
cancer types.

133

APPENDIX 1

Compounds identified in our HTS of autophagy modulators were classified by 3 dimensional steric
fingerprinting by Dr. David Maxwell, Department of Experimental Therapeutics, MDACC
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APPENDIX 2
_________________________________________________________
Protein expression profile of cancer cell lines treated with perphenazine
normalized to corresponding DMSO treatment at each timepoint (0, 0.5,
1,3,6,12,24 hr). Protein status is represented as: red for upregulated
protein expression, and green for downregulated protein expression
level.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Tissue of Origin
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Melanoma
Melanoma
Melanoma
Melanoma
Osteosarcoma
Ovarian
Ovarian
Prostate
Prostate

Cell Line
BT-549
MCF-7
MCF-10A
MDA-MB-231
MDA-MB-468
SKBR3
T47D
ZR75-1
Mel 624
MEWO
SKMEL-5
WM 35
U2-OS
SKOV-3
OVCAR-3
LNCaP
PC3
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1*
BT549 / Breast

140

2*
MCF-7 / Breast

141

3*
MCF-10A / Breast

142

4*
MDA-MB-231 / Breast

143

5*
MDA-MB-468 / Breast

144

6*
SKBR3 / Breast
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7*
T47D / Breast

146

8*
ZR-751 / Breast

147

9*
Mel 624 / Melanoma

148

10*
MEWO / Melanoma
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11*
SKMEL5 / Melanoma

150

12*
WM35 / Melanoma
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13*
U2OS /
Osteosarcoma
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14*
OVCAR3 / Ovarian

153

15*
SKOV3 / Ovarian

154

16*
LNCaP / Prostate

155

17*
PC3 / Prostate
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